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SUMMARY OF THE THESIS 
 
Bisphosphonates (BISs) are widely used for the treatment of osteoporosis and tumors with 
bone metastasis to inhibit osteoclast activity and bone resorption. Although BIS treatment 
undoubtedly improves the quality of life, osteonecrosis is a rare, but serious adverse effect 
that occurs mainly after invasive dental procedures, e.g. tooth extraction, with an increased 
incidence particularly after the use of third-generation BISs (e.g. zoledronate, ZOL). BISs 
together with other antiresorptive and antiangiogenic drugs induce necrosis of the oral 
bones, usually referred to as medication-related osteonecrosis of the jaw (MRONJ), but 
bone destruction is also seen less frequently in other bones of the skeleton. We 
hypothesized that a disturbed mandibular microcirculation may play a role in the 
pathogenesis of MRONJ. In this context, we designed a rat model where chronic BIS 
treatment was combined with an invasive dental procedure and where the processes of 
mucosal healing and bone destruction resembled the clinical manifestations of MRONJ. 
ZOL was applied intravenously (in a dose of 80 µg/kg/week) over 8 weeks, the first two 
right mandibular molar teeth were extracted in the third week, and various systemic and 
local parameters of the inflammatory cascade were investigated 6 weeks after tooth 
extraction. The incidence and severity of the gingival lesions were determined on the basis 
of a new scoring system, while jaw osteonecrosis was diagnosed by means of computed 
micro tomography. We also developed a method by which the mandibular periosteum can 
be visualized relatively simply and highly reproducibly by means of different microscopy 
methods (fluorescence intravital microscopy, orthogonal spectral imaging and confocal 
laser scanning microscopy) in rats. Furthermore, we compared the effects of chronic ZOL 
administration on the mandibular and tibial periosteal microcirculatory reactions (with or 
without tooth extraction). Intravital fluorescence videomicroscopy revealed significantly 
increased leukocyte–endothelial interactions (leukocyte rolling and adhesion on the 
endothelial surface) in the mandibular periosteum, but not in the tibia. Only the leukocyte 
count and NADPH-oxidase activity of the leukocytes displayes significant reductions, the 
other systemic inflammatory parameters not being affected by ZOL. We conclude that 
chronic ZOL treatment causes a distinct microcirculatory inflammatory reaction in the 
mandibular periosteum, but not in the tibia. The local reaction in the absence of augmented 
systemic leukocyte inflammatory activity suggests that topically different, endothelium-
specific changes may play a critical role in the pathogenesis of MRONJ. 
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1. INTRODUCTION 
1.1. Inflammatory processes in the oral and maxillofacial region. The potential role 
of periosteal reactions 
The oral cavity is particularly prone to inflammatory complications (e.g. 
periodontitis or abscesses), as it can be sensitively exposed to the external environment in 
the immediate vicinity of the teeth. The propagation of various infection-related 
inflammatory reactions within the soft tissues (e.g. sinusitis, phlegmon or intracranial 
abscesses) is at least partially due to the rich blood supply of the oral and maxillofacial 
region, favoring the spread of these inflammatory processes. A special nutritive aspect of 
the jaw (i.e. it is predominantly supplied by the periosteal circulation) also predisposes to 
various pathological conditions of the bones, ranging from abscess formation to the more 
severe osteomyelitis and osteonecrosis [Scoletta M 2010]. The present thesis is based on 
the assumption that morphological and functional changes in the microcirculation in the 
periosteum play a decisive role in the pathogenesis of various mandibular pathologies. 
In general, the role of the periosteal integrity in bone physiology is well recognized, 
not only as it relates to the maintenance of the vascular supply, but also from the aspect of 
the active regulation of the bone metabolism and regeneration. It is similarly well known 
that successful healing after fractures requires the regeneration of the peri- and endosteal 
circulations [Macnab I 1974]. Likewise, periosteal damage leads to perturbed bone healing 
with consequent delayed union or pseudoarthrosis formation [Utvag SE 1998, Gustilo RB 
1990, Esterhai JL 1991]. With regard to the mandible, clinical observations show that 
defective angiogenesis of the mandibular mucoperiosteal tissues is evoked by long-term 
treatment with bisphosphonate (BIS), resulting in severe conditions such as osteonecrosis 
of the jaw [Wehrhan F 2011]. It follows that periosteal microvascular alterations can be of 
importance in the pathomechanism of oral diseases associated with a deterioration of tissue 
perfusion and with inflammatory complications.  
 
1.2. Special features of the jaw bones with respect to the blood and nerve supply 
and bone remodeling 
The continuous blood supply of the bones is necessary in order to ensure 
physiological bone remodeling, metabolism and regeneration, but differences are observed 
within the skeletal system. While the appendicular long bones receive their vascular supply 
from the nutritive arteries, the epiphyseal and metaphyseal vessels [Hooper 1987, Johnson 
EO 2004, Findlay DM 2007], the circulation of the maxillofacial bones, and especially the 
8 
 
lower jaw, is provided by the mucoperiosteal tissue through the inferior alveolar and 
sublingual arteries [Huelke DF 1965, Shannon J 2011]. This underlines the role of the 
periosteum in the bone remodeling and regeneration processes of the jawbones [Støre G 
1999, Elshahat A 2004]. The innervation pattern of the mandible also differs from that of 
appendicular long bones such as the tibia. The mandibular nerve, the third and inferior 
division of the trigeminal nerve, provides the innervation of the lower third of the 
maxillofacial region, containing both afferent and efferent fibers [Rodella LF 2012]. While 
networks of nerves spread across the surface of the mandible, the tibial periosteum displays 
a longitudinal orientation. Vasoactive intestinal polypeptide-positive nerve fibers also form 
small networks with individual fine varicose fibers in the mandibular periosteum, whereas 
larger networks are to be seen at the tibia. These fine fibers are associated with both 
vascular and nonvascular elements, suggesting specific functions in the mandibular 
periosteum [Hill EL 1991].  
The jaw region additionally possesses particular regeneration and remodeling 
characteristics. As opposed to long bone fractures, which heal mainly through 
endochondral ossification, intramembranous ossification has a higher impact in the 
mandible [Yu YY 2012]. In line with this, periosteum-derived stem cells, which play an 
important role in the bony regeneration processes, have been shown to possess the highest 
osteogenic potential in the mandible, while tibial periosteum or bone marrow stem cells are 
superior in terms of chondrogenesis [Park JB 2012]. Further, mandible bone marrow stem 
cells have been demonstrated to have a marked capacity to induce bone formation both in 
vitro and in vivo [Aghaloo TL 2010]. The fact that this phenomenon may be observed in 
vivo [Schmidt BL 2002, Ueno T 2002] indicates that the mandible possesses a particularly 
high degree of osteogenesis potential among the different anatomical locations [Solheim E 
1995]. It was recently shown that distinct differences in the expression pattern of bone 
development-related genes exist between mandibular and tibial osteoblasts [Reichert JC 
2013]. Systemic disorders such as osteoporosis have also been reported to influence bone 
remodeling differently in the mandible and the tibia, the mandible being significantly less 
affected in experimental osteoporosis [Yamashiro T 1998, Mavropoulos A 2007, Liu H 
2014]. Intense mechanical loading of the alveolar process during mastication may protect 
the alveolar bone from the osteoporosis-related bone loss observed at other skeletal sites 
[Mavropoulos A 2007].  
BISs also exert unique effects on the bones in the maxillofacial region. The regional 
BIS uptake reaches a higher concentration in the mandible in comparison with the 
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appendicular and other axial bones [Wen D 2011]. The receptor activator of nuclear factor 
κB (RANK)/receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin axis, 
a signaling pathway that regulates osteoclast differentiation and activation, is also diversely 
affected by BIS, causing a decrease in RANKL values in the mandible and the opposite 
effect in the tibia [Çankaya M 2013]. Furthermore, BIS treatment exerts site differential 
effects during the early healing processes of tibial and mandibular fractures by delaying 
callus, cartilage and bone remodeling specifically in the mandible [Yu YY 2012]. The 
potential regional differences in microcirculatory reactions, however, are less well clarified. 
 
1.3. Microcirculatory inflammatory reactions 
 Acute inflammation is a complex biological response of the cells, tissues and organs 
to harmful stimuli, such as pathogens, damaged cells or irritants. Almost all of the cardinal 
symptoms (redness/rubor, swelling/tumor, increased heat/calor, pain/dolor, and loss of 
function/functio laesa) can be linked to changes in the microcirculation. Behind these 
symptoms, characteristic changes within the microcirculation can be evidenced such as (1) 
an impaired vasomotor function, (2) decreased capillary perfusion, (3) increased 
microvascular permeability, (4) activation of the coagulation cascade and enhanced 
thrombosis, and (5) the adherence of leukocytes and platelets.  
Tissue trauma or ischemia–reperfusion brings about a very complex antigen-
dependent or independent activation of the immune system. Briefly, infection, oxido-
reductive stress or tissue disintegration (usually caused by free radical-mediated injury) 
creates noxious signals which lead to the release of pro-inflammatory cytokines such as 
complements, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and -6 (IL-
6) and also induce direct endothelial injury [Serrick C 1994, Kurose I 1997, Carden DL 
2000, Loukas M 2008]. In the initial phase, a local hyperemic reaction occurs as a result of 
the rapid release of vasoactive mediators (histamine, bradykinin, neuropeptides, 
prostaglandins and nitric oxide) produced by inflammatory cells (mast cells, macrophages, 
fibroblasts, parenchymal and endothelial cells) [Cooper D 2002]. These changes are also 
associated with an increase in microvascular permeability/edema formation promoted by 
various mediators (histamine, bradykinin, leukotrienes, platelet activating factor, substance 
P and the vascular endothelial growth factor (VEGF)), the activation of neutrophil 
leukocytes resulting in further tissue injury through the transmigration of 
polymorphonuclear leukocytes (PMN) [for a review, see Kvietys PR 2012].  
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A complex activation of the inflammatory cascade is initiated through the release of 
chemoattractants, leading to the activation of PMNs and promoting their accumulation 
within and around the injured tissue. These processes result in the enhanced expression of 
various adhesion molecules on the surface of leukocytes and endothelial cells, such as 
immunoglobin-like adhesion receptors (intercellular adhesion molecule-1, platelet 
endothelial cell adhesion molecule-1 and vascular cell adhesion molecule-1), integrins 
(CD11/CD18), and selectins (E-, P- and L-selectin) [Springer TA 1990, Eppihimer MJ 
1997]. This is followed by the adhesion of PMNs and platelets to the activated 
endothelium, with the resultant development of cell-to-cell interactions (rolling, sticking 
and migration of PMNs) [Wanner GA 1996, Loukas M 2008]. The PMNs produce further 
reactive oxygen species via NADPH-oxidase and myeloperoxidase and release the 
lysosomal enzymes elastase, collagenase and phospholipase, which promote tissue necrosis 
and apoptosis [Cooper D 2002]. The propagation of inflammatory processes toward remote 
organs is mediated by activated PMNs or the spreading of pro-inflammatory cytokines 
[Springer TA 1990, Eltzschig HK 2004, Tapuria N 2008].  
Free radicals, nitric oxide and PMNs have been shown to play a role in various oral 
inflammatory and neoplastic diseases [Battino M 1999, Scott DA 2012, Choudhari SK 
2013]. Furthermore, inflammatory processes play a part not only in oral pathologies, but 
also in bone healing [Thomas MV 2011]. An increased release of pro-inflammatory 
cytokines has been demonstrated in chronically BIS-treated patients [Sharma D 2013].  
 
1.4. Assessment of the periosteal microcirculatory reactions in intraoral and 
systemic diseases 
Studies of the microcirculation in the oral region attracted considerable attention 
when the predictive value of mucosal perfusion deficits was demonstrated in septic shock 
patients [Verdant CL 2009, Top AP 2011]. Another intraoral manifestation of a systemic 
menace was revealed during cardiac surgery [Bauer A 2007] and the intraoral 
microcirculation proved to correlate well with the gastrointestinal perfusion changes 
[Verdant CL 2009]. On the other hand, oral infection may also exert systemic effects as the 
blood-borne oral lipopolysaccharides and oral bacteria have been shown to provoke the 
release of the cytokines (e.g. IL-6 and TNF-alpha), which in turn brings about an acute 
phase response [Williams RC 2005]. The periosteal microcirculatory aspects of systemic 
and intraoral diseases, however, have been far less well clarified.  
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The vascular architecture of the intraoral region, including the periosteum, can be 
examined by imaging methods such as computer tomography (CT), magnetic resonance 
imaging and to some extent scintigraphy or histology [Berggren A 1982, Nobuto T 1989, 
Bhatt R 2000, Fayad LM 2005]. 
Nevertheless, these tools are not relevant when dynamic changes or functional 
aspects of the periosteal microcirculation are to be investigated. The methods utilized for 
examinations of the functional characteristics of the microcirculation, such as hemoglobin 
absorptiometry combined with laser-Doppler flowmetry, may provide information on tissue 
oxygenation and perfusion, but in this case the tissue mass is rather robust, e.g. the gingival 
[Milstein DM 2013]. If more accurate detection or improved spatial resolution of the 
microcirculation is needed, fluorescence intravital microscopy (IVM) can provide an 
opportunity for real-time examination of the microcirculation of superficial layers of 
different organs. Conventional fluorescence IVM has many advantages. It can visualize not 
only changes in the efficacy of microvascular perfusion, but also leukocyte–endothelial 
interactions (such as rolling and adhesion), metabolic variables or signs of apoptosis [Horie 
Y 1996, Abshagen K 2006].  
 For observation of the microcirculation of superficial tissue layers, nonfluorescence 
techniques such as orthogonal polarization spectral imaging (OPS) [Groner W 1999] and 
sidestream dark-field imaging have also been developed [Milstein DM 2010]. These 
methods have the advantage that the use of fluorescence markers is not necessary and this 
allows the possibility of human applications in the oral cavity [Milstein DM 2010, De 
Backer D 2013]. Observation of the periosteal compartment would still necessitate surgical 
exposure, but the imaging of individual vessels and cells is possible without disturbing their 
functional characteristics.  
 The calvarian periosteum can be visualized in experimental settings [Stuehmer C 
2009], but examination of the microcirculation of the jaw bones runs into many technical 
difficulties. We earlier developed methods suitable for visualization of the tibial periosteum 
and the synovial membrane in the knee joint in rats [Varga R 2008, Hartmann P 2012], but 
such approaches were not available for the exposure and in vivo investigation of the 
mandibular periosteum. We therefore considered it important to address this issue, in part 
to solve the technical problems and in part because the physiology or the 
pathophysiological reactions of the jaw may differ from those in other bones of the 
skeleton. Specifically, BISs have been demonstrated to cause osteonecrosis in the jaw after 
invasive dental procedures, but such reactions do not occur in the bones of the appendicular 
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skeleton [Stadelmann VA 2008, Blazsek J 2009]. This observation suggests that potentially 
different microcirculatory reactions may evolve in the periosteum at different anatomical 
locations. For this reason, in Study 1 we set out to compare the microcirculatory 
characteristics of the mandibular and the tibial periosteum through the use of a 
microsurgical approach and microscopic methods that are suitable for the in vivo 
visualization of individual microvessels.  
 
1.5. Medication-related osteonecrosis of the jaw (MRONJ) 
1.5.1. Pharmacology of BISs 
BISs are widely used for the treatment of rheumatologic and oncological diseases 
with bone metastasis and are commonly administered in osteolytic conditions (e.g. Paget’s 
disease and myeloma multiplex) [Ruggiero SL 2014].  
BISs are pyrophosphate analogs in which oxygen is replaced by a carbon atom, 
resulting in a backbone P-C-P which is stable against enzymes with hydrolytic activity. 
Although BISs have a similar core structure, they also contain two side-chains or groups, 
R1 and R2, attached to the central carbon atom. All the recently developed BISs contain a 
hydroxy side-group at position R1, increasing their binding to bone. Differences in the 
physicochemical and biological properties of BISs are due to the differences in the R2 side-
group, where the presence of nitrogen and its orientation within the R2 side-chain can 
influence their overall potency [Luckman SP 1998, Rodan GA 1998, Mönkkönen H 2006, 
Ebetino FH 2011, Rogers MJ 2011]. 
 The BISs are generally classified as first- (e.g. etidronate, clodronate), second- (e.g. 
alendronate and pamidronate) or third-generation (e.g. zoledronate (ZOL), olpadronate and 
neridronate) compounds. The taxonomy of BISs based on their chemical structure, such as 
their nitrogen content, is clinically more relevant as more severe side-effects (i.e. 
osteonecrosis) have been attributed to BISs containing nitrogen [Marx RE 2003, Ruggiero 
SL 2014]. The main therapeutic effect of BISs is linked to the inhibition of the activity and 
apoptosis induction of osteoclasts altering the bone metabolism (Figure 1) [Rodan GA 
1998, Brozoski MA 2012]. This leads to the inhibition of bone resorption and a reduction 
of bone turnover [Borozoski MA 2012], but the mechanism of action shows differences as 
a function of the nitrogen content. Non-nitrogen-containing BISs (etidronate and 
clodronate) are intracellularly incorporated, their accumulation leading to osteoclast 
apoptosis by inhibiting ATP-dependent enzymes [Rodan GA 1998, Rogers MJ 2011]. The 
more potent nitrogen-containing BISs (alendronate, ZOL and pamidronate) inhibit farnesyl 
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diphosphate synthase, which is responsible for an enzymatic process during the mevalonate 
pathway (cholesterol synthesis), inducing apoptosis and decreasing the functional activity 
of osteoclasts [Luckman SP 1998, Rodan GA 1998, Mönkkönen H 2006, Ebetino FH 2011, 
Rogers MJ 2011]. 
 Depending on the therapeutic indication and the severity of the skeletal disorders, 
these drugs can be administered orally or intravenously (i.v.) in different doses and 
frequencies. However the biological utilization during gastrointestinal absorption is not 
appropriate (~ 1%), while 60% of i.v. administered BISs can bind to the bone surface [Ezra 
A 2000]. Owing to their long half-life (~ 10 years), the effects of BISs on bone remodeling 
can be evidenced for several years [Brozoski MA 2012].  
 Antiangiogenic effects of BISs are also known. This feature is particularly favorable 
in oncological cases, where this adjuvant treatment reduces tumor invasion and the 
progression of bone metastases. Antiangiogenic effects of BISs brought about by the 
modification of VEGF or VEGF receptor expressions or by other factors have been 
observed in both in vitro [Wood J 2002, Ziebart T 2013] and in vivo studies [Fournier P 
2002, Bigi MM 2010, Guevarra CS 2013, Smidt-Hansen T 2013, Ohba T 2014, Pabst AM 
2014]. BISs can inhibit the migration of different cell types, influencing regeneration [Koch 
FP 2011, Ziebart T 2013, Hagelauer N, 2014, Ohba T 2014], and also modulate 
immunological processes [Fujimura T 2013, Sasaki O 2013, Kalyan S 2014].  
 
 
Figure 1.  The effects of BIS [based on Holen I 2010] 
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1.5.2. Side-effects of BISs. Osteonecrosis of the jaw 
 Treatment with BISs induces various side-effects with relatively high incidence. 
These include influenza-like symptoms after the first BIS administration, but mucosal 
irritation, hypocalcemia, cardiac conduction disturbances and an impaired renal function 
have also been reported [Bunyaratavej N 2009, Han GY 2009, Rossini M 2013]. 
 Although BIS treatment undoubtedly improves the quality of life of the patients 
[Endo N 2012, Kerschan-Schindl K 2012, Wilson S 2012], osteonecrosis is a serious 
adverse effect in a number of cases [Kühl S 2012, Yamashita J 2012]. BIS-related 
osteonecrosis of the jaw was first reported in 2003 [Marx RE 2003], but it was later proven 
that other antiresorptive (e.g. denosumab) [Aghaloo TL 2010, Niibe K 2014, O'Halloran M 
2014, Vyas S 2014] and antiangiogenic (e.g. bevacizumab or sunitinib) drugs [Serra E 
2009, Van Poznak C 2010, Koch FP 2011] also bring about MRONJ [Ruggiero SL 2014]. 
This occurs mainly after invasive dental procedures, e.g. tooth extraction or a periodontal 
disorder [Kang B 2013, Ruggiero SL 2014], with an increased incidence particularly after 
the use of third-generation BISs (e.g. ZOL) [Drozdzowska B 2011, Brozoski MA 2012]. 
MRONJ occurs predominantly in molar and premolar regions in the mandible [Ruggiero 
SL 2009, Otto S 2012].  
The most recently position paper published by the American Association of Oral 
and Maxillofacial Surgeons specifies that MRONJ can be divided into the following stages 
with (a)typical symptoms (Table 1) [Ruggiero SL 2014]: 
 
Stages 
Common complaints 
of the patient 
Clinical manifestations Radiological findings 
Patients 
at risk 
no apparent necrotic bone in asymptomatic patients treated orally or i.v. with 
an antiresorptive or antiangiogenic drug 
0 atypical symptoms 
(odontalgia, dull, 
aching bone pain, 
sinus pain) 
no necrotic bone, 
loosening of teeth, 
periapical/periodontal 
fistula without pulpal 
necrosis  
alveolar bone loss, 
changes in trabecular 
pattern, osteosclerosis, 
periodontal ligament 
thickening (Figure 2A) 
1 no symptoms exposed and necrotic 
bone, or fistula without 
signs of infection 
see above  
2 pain see above + infection  see above 
3 pain see above + osteolysis  
(Figure 2B) 
see above 
Table 1. Stages of MRONJ [Ruggiero SL 2014]. 
 
 
15 
 
A         B 
 
 
Figure 2. Radiological manifestation of the osteonecrosis on the right side of the mandible in a BIS-
treated patient (A). Clinical manifestation of bilateral, extended osteonecrosis of the maxilla in 
another BIS-treated patient (B). 
 
 Many theories and risk factors have been taken into account during examinations of 
the pathogenesis of MRONJ [Mehrotra B 2006]. The epidemiological data on MRONJ are 
often not comparable because of its multifactorial etiology [Yamashita J 2010]; insomuch 
as it can be influenced by the administered drug (orally or i.v., non-/nitrogen-containing 
BIS), the duration of the therapy, the indication of BIS administration (osteoporosis, 
oncological reason or other), co-morbidities, the concomitant use of other drugs 
(corticosteroids or chemotherapeutic drugs), poor oral hygiene, genetic factors (CYP2C8) 
[Sarasquete ME 2009], age, an invasive dental procedure and other conditions 
[Drozdzowska B 2011, Brozoski MA 2012, Ruggiero SL 2014]. Local contamination and 
infection evoked by invasive dental procedures in the presence of BIS treatment have also 
been emphasized in the development of MRONJ [Mawardi H 2011, Wei X 2012], since 
BISs can take part in the development of biofilm formation [Sedghizadeh PP 2008, Kumar 
SK 2010]. Osteonecrosis, however, can develop several years later, which may be 
explained by the long half-lives of these medications [Brozoski MA 2012] and not by the 
acute infectious induction. Moreover, BIS treatment has been shown to cause sterile 
inflammatory reactions such as aseptic peritonitis [Calligeros D 1993, Norton JT 2011] and 
an enhancement of leukocyte–endothelial cell interactions in the knee joint [Zysk SP 2003]. 
These effects may be linked to an upregulation of pro-inflammatory cytokines such as IL-1 
and TNF-alpha [Zysk SP 2003, Norton JT 2011, Anastasilakis AD 2012] in response to 
BIS administration. The effects of BIS also show spatial differences, because certain 
inflammatory reactions were confined to the mandible, but were not present in the femur 
[Senel FC 2010]. In another model, the stability of femoral implants was even enhanced 
after BIS treatment [Stadelmann VA 2008]. Nevertheless, the exact pathomechanism of 
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MRONJ has not yet been clarified, and the possibilities of its prevention or the use of 
curative modalities are also limited. 
Tooth extraction is normally accompanied by tissue ischemia, which initiates a 
cascade of inflammatory reactions promoting the expression of different hypoxia-induced 
angiogenic substances [Sharma D 2013]. Among these factors, a considerable contribution 
of VEGF in the pathogenesis of MRONJ can be presumed. Specifically, antibodies against 
VEGF alone induce osteonecrosis of the mandible [Pakosch D 2012] and bevacizumab 
increases the incidence of MRONJ [Aragon-Ching JB 2009]. The predictive value of 
plasma VEGF levels regarding the risk of MRONJ has also been assumed [Vincenzi B 
2012]. Further, BIS treatment has been shown to downregulate the expression of 
angiogenic factors, with the simultaneous upregulation of inflammatory cytokines [Mozzati 
M 2012]. This is supported by the fact that BIS treatment combined with an anti-
angiogenic drug (bevacizumab) can also increase the prevalence of MRONJ [Aragon-
Ching JB 2009].  
 The periosteal perfusion significantly influences bone healing and determines the 
prognosis of adjacent soft tissue traumas as well [Schaser KD 2003]. However, little is 
known about the microcirculatory effects of BIS, and especially the microcirculation of the 
mandible. Likewise, no data are available to date on the periosteal changes after invasive 
dental procedures involving BIS treatment. In Study 2, we hypothesized that a disturbed 
mandibular microcirculation may play a role in the pathogenesis of MRONJ. 
  
2. MAIN GOALS 
 
The main goals of the present studies were: 
1. To develop a novel microsurgical procedure for the in vivo visualization of the 
mandibular periosteal microcirculation through the use of different microscopy 
methods (fluorescence IVM, OPS and confocal laser scanning microscopy (CLSM)) 
in rats. 
2. To examine the systemic and local mandibular periosteal inflammatory 
microcirculatory reactions in comparison with those in the tibia in a clinically 
relevant model of BIS-induced MRONJ in rats. 
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3. MATERIALS AND METHODS 
 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) unless indicated 
otherwise. The study was performed in accordance with the Guidelines laid down by the 
National Institutes of Health (NIH) in the USA regarding the care and use of animals for 
experimental procedures, and with the 2010/63/EU Directive and was approved by the 
Animal Welfare Committee of the University of Szeged (V/1639/2013). 
 
3.1. Microsurgical exposure of the mandibular and tibial periosteum for in vivo 
microscopic examinations 
 Sprague-Dawley rats (their average weight at the time of the experiment was 320 ± 
10 g) were anesthetized intraperitoneally (i.p.) with an initial dose of sodium pentobarbital 
(45 mg/kg). After cannulation of the trachea, the penile vein was cannulated to administer 
fluids and drugs (supplementary dose of sodium pentobarbital: 5 mg/kg). During 
preparation and microcirculatory investigations, the rats were placed in a supine position on 
a heating pad to maintain the body temperature at 36-37 °C. 
For in vivo examination of the mandibular periosteum, the fur of the animals in the 
mandibular region was shaved, and a lateral incision parallel to the incisor tooth was made 
in the facial skin and the underlying subcutaneous tissue, using a careful microsurgical 
approach under an operating microscope (6x magnification; Carl Zeiss GmbH, Jena, 
Germany). The masseter muscle consists of superficial and deep parts, the latter being 
further divided into anterior and posterior sections in rats [Cox PG 2011]. The fascia 
between the anterior part of the deep masseter and the anterior superficial masseter was cut 
with microscissors (Figure 3A). By this means, the periosteal membrane covering the 
corpus of the mandible laterally to the incisor tooth was reached and it was gently separated 
from the covering thin connective tissue (Figure 3B). Stitches with 7.0 monofilament 
polypropylene microsurgical thread were placed into the surrounding masseter muscles for 
retraction and better exposure of the region of interest. We applied this surgical approach 
on both sides of the lower jaw. With this preparation technique, the periosteal 
microcirculation of the mandible could be examined by in vivo microscopic methods at the 
anterior margin of the molar region. 
 The medial/anterior surface of the tibia was exposed by complete transection of the 
anterior gracilis muscle with microscissors, and careful atraumatic microsurgical removal 
of the connective tissue covering the tibial periosteum (Figure 3C,D) [Varga R 2008].  
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3.2. Experimental protocols 
3.2.1. Protocol for in vivo examination of the microcirculatory characteristics of the 
mandibular periosteum using different microscopic approaches in rats 
 In Study 1, 10 male Sprague-Dawley rats were used. After the surgical procedures 
and exposure of the mandibular and tibial periosteum on both sides, recordings were 
performed on the right side with OPS, which does not require any fluorescence labeling. 
After this, the animals received i.v. injections of fluorescein isothiocyanate (FITC)-labeled 
erythrocytes (0.2 mL; Sigma Aldrich) (Figure 5A,B) [Ruh J 1998] and rhodamine-6G 
(0.2%, 0.1 mL; Sigma Aldrich) for the staining of leukocytes (Figure 3C,D), and IVM 
recording was performed at the previous locations. Subsequently, 50 µL of the nuclear dye 
acriflavin (1 mM) was applied topically to the tibial periosteal surface on the left side, and 
rinsed off with warm physiological saline solution after an exposure time of 1 min, and 
CLSM recording was then performed (Figure 6B). The same staining procedure was 
carried out for the mandible on the left side (Figure 6A). This was followed by an i.v. 
injection of the plasma dye FITC-dextran 150 kDa (0.3 mL, 20 mg/mL solution dissolved 
in saline; Sigma Aldrich), and CLSM (Figure 6C,D) and IVM recordings (Figure 5E,F) 
were made on the tibia and the mandible on the right side 5 min after the injection of the 
tracer. 
 The exposed periosteum of the corpus of the mandible or the tibial periosteum on 
the right side was positioned horizontally on an adjustable stage and superfused with 37 °C 
saline. The periosteal membranes were first visualized with an OPS device (Cytoscan™, 
Cytometrics, PA, USA), which provides optimal imaging of the microvascular structures at 
a chosen focus level (penetration depth: approx. 200 µm [Groner W 1999]) (Figure 4A,B). 
This technique utilizes epi-illumination with linearly polarized light at 548 nm (which is 
the isobestic point of oxy- and deoxyhemoglobin) to visualize hemoglobin-containing 
structures without the additional use of a fluorochrome. Images were recorded on a SVHS 
video recorder (Panasonic AG-MD 830; Matsushita Electric Industrial Co., Tokyo, Japan) 
and a personal computer. 
Confocal imaging of the surface of the mandibular and tibial periosteum was 
performed with a Five1 Optiscan device (Optiscan Pty. Ltd., Melbourne, Victoria, 
Australia) (Figure 6). In vivo histology was employed by placing the Optiscan probe on the 
surface of the periosteal membranes and by changing the focus level through virtual 
sections of 7 µm during the confocal imaging (penetration depth: 0-250 µm). Cell nuclei 
were first stained with topically applied acriflavin (see above) on the left side, and this was 
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followed by recordings on the contralateral side after i.v. injection of the intravascular 
tracer FITC-dextran (see above). Images were stored on a personal computer provided by 
the manufacturer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Exposure of the mandibular and tibial periosteum for in vivo microscopic examinations. 
Access to the mandibular periosteum was achieved by making a lateral incision parallel to the 
incisor tooth in the facial skin and the underlying subcutaneous tissue, which was followed by 
gentle separation of the fascia between the anterior part of the deep masseter (dm) and the anterior 
superficial masseter (asm) muscles (A, B). Finally, the thin connective tissue covering the 
periosteum was gently incised with microscissors. By this means, the periosteal membrane covering 
the corpus of the mandible laterally to the incisor tooth was reached. The tibial periosteum was 
reached by transecting the anterior gracilis (ag) muscle completely in the middle (and a part of the 
posterior gracilis muscle (pg) too) and gently removing the thin connective tissue covering the 
periosteum (C, D). The bar denotes 2,500 µm. 
 
3.2.2. Protocol for the induction of BIS-induced osteonecrosis and examination of its 
periosteal microcirculatory consequences in rats 
 In Study 2, 20 male Sprague-Dawley rats were randomly allocated to saline vehicle-
treated control (n=10), or i.v. ZOL-treated (n=10, ZOL) groups. ZOL (Zometa®; Novartis 
Europharm, Budapest, Hungary) was administered through a tail vein in a dose of 80 μg/kg 
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once a week for 8 weeks. At the end of the 3rd week of the protocol, the first and second 
molar teeth on the right side were extracted from the mandible under ketamine and xylazine 
(i.p. 25 and 75 mg/kg, respectively) anesthesia. The teeth were luxated with an 18G needle 
and the extraction was performed with extraction forceps. The roots were also removed 
with a dental drill under a Zeiss operating microscope (6x magnification, Carl Zeiss GmbH, 
Jena, Germany). By these means, the defect was equal in size and severity in all rats. For 
pain relief, intramuscular ketoprofen (Ketodex Forte, Berlin-Chemie AG, Berlin, Germany; 
5 mg/kg) and oral metamizole sodium (Algopyrin, Sanofi-Aventis, Budapest, Hungary; 75 
mg/kg) were administered for 3 days. Mucosal healing processes were monitored 
continuously throughout the experimental period. Through fluorescence IVM, the 
microcirculatory variables were compared in the mandibular and tibial periosteum in the 
9th week of the protocol. FITC-labeled erythrocytes (0.2 mL i.v.) were used to stain red 
blood cells, and rhodamine-6G (0.2%, 0.1 mL i.v.) to stain leukocytes. Leukocyte 
function/activation and inflammation were examined by assessing the NADPH-oxidase 
activity of neutrophil leukocytes, whole blood free radical production, the expression of 
CD11b adhesion molecule on neutrophil leukocytes and the plasma TNF-alpha content. 
The incidence and severity of mucosal lesions were also assessed. Mandibular 
osteonecrosis was evidenced by computed microCT analysis and standard histology (see 
later). 
 
3.3. Methods for the visualization of the mandibular and tibial periosteal 
microcirculation 
3.3.1. OPS technique 
In Study 1, the periosteal membranes were first visualized with an OPS device 
(Cytoscan™, Cytometrics, Philadelphia, PA, USA), which provides optimal imaging of the 
microvascular structures at a chosen focus level (penetration depth: approx. 200 m; 
[Groner W 1999]) (Figure 4 A,B). This technique utilizes epi-illumination with linearly 
polarized light at 548 nm (which is the isobestic point of oxy- and deoxyhemoglobin) to 
visualize hemoglobin-containing structures without the additional use of a fluorochrome. 
Images were recorded on a SVHS video recorder (Panasonic AG-MD 830; Matsushita 
Electric Industrial Co., Tokyo, Japan) and a personal computer. 
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Figure 4. Micrographs showing the mandibular (A) and tibial (B) periosteum, made with the OPS 
imaging technique. The bar denotes 200 µm. 
 
3.3.2. Fluorescence IVM 
In both studies, the periosteal microcirculation was visualized by IVM (penetration depth: 
approx. 250 m; Zeiss Axiotech Vario 100HD microscope; 100-W HBO mercury lamp; 
Acroplan 20 x / 0.5 N.A. W, Carl Zeiss GmbH, Jena, Germany). Images from 3 or 4 fields 
of the mandibular and the tibial periosteum (Figure 5) were recorded with a charge-coupled 
device video camera (Teli CS8320Bi, Toshiba Teli Corporation, Osaka, Japan) attached to 
an S-VHS video-recorder (Panasonic AG-MD 830; Matsushita Electric Industrial Co., 
Tokyo, Japan) and a personal computer (see the labeling techniques above). 
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Figure 5. Fluorescence IVM images of the mandibular (A, C, E) and the tibial (B, D, F) periosteum, 
involving FITC-labeled erythrocytes (A, B), rhodamine 6G-labeled neutrophil leukocytes (C, D) 
and FITC-dextran-labeled plasma (E, F). The bar denotes 200 µm. 
 
3.3.3. Fluorescence CLSM 
In Study 1, confocal imaging of the surface of the mandibular and tibial periosteum was 
performed with a Five1 Optiscan device (Optiscan Pty. Ltd., Melbourne, Victoria, 
Australia) (Figure 6). In vivo histology was employed by placing the Optiscan probe on the 
surface of the periosteal membranes and by changing the focus level through virtual 
sections of 7 m during the confocal imaging (penetration depth: 0-250 m). Cell nuclei 
were first stained with topically applied acriflavin (see above) on the left side, and this was 
followed by recordings on the contralateral side after i.v. injection of the intravascular 
tracer FITC-dextran (see above). Images were stored on a personal computer provided by 
the manufacturer.  
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Figure 6. CLSM images of the mandibular (A, C) and tibial (B, D) periosteum. Cell nuclei were 
labeled by the topical application of acriflavin (left side) (A, B).  Images were also taken at both 
structures on the right sides after the i.v. injection of FITC-dextran (C, D). The bar denotes 200 µm. 
 
3.3.4. Video analysis 
Quantitative evaluation of the microcirculatory parameters was performed off-line by 
frame-to-frame analysis of the videotaped images taken for IVM and OPS (IVM Software; 
Pictron Ltd, Budapest, Hungary). Leukocyteendothelial cell interactions were analyzed in 
at least in 4 postcapillary venules per rat. Rolling leukocytes were defined as cells moving 
with a velocity less than 40% of that of the erythrocytes in the centerline of the microvessel 
and passing through the observed vessel segment within 30 s, and are given as the number 
of cells per second per vessel circumference. Adherent leukocytes were defined as cells that 
did not move or detach from the endothelial lining within an observation period of 30 s and 
are given as the number of cells per mm2 of endothelial surface, calculated from the 
diameter and length of the vessel segment. Red blood cell velocity (RBCV, µm/s) was 
determined by frame-to-frame analysis of 5-6 consecutive video-captured images taken 
after labeling of the erythrocytes (see above). 
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3.4. Measurement of systemic inflammatory parameters 
3.4.1. Leukocyte count 
1.5 mL of blood was collected from the penile vein in a tube with EDTA and was held on 
ice. 100 µL was mixed with Turks solution (0.2 mg gentian violet in 1 mL of glacial acetic 
acid, 6.25% v/v) in 1:20 dilution. Leukocytes were determined as monomorphonuclear 
cells and PMNs in a hematocytometer. 
 
3.4.2. Flow cytometric analysis of CD11b expression changes 
The surface expression of CD11b on the peripheral blood granulocytes was determined by 
flow cytometric analysis as detailed elsewhere [Szabó A 2011]. One-hundred μL of whole 
blood was incubated with 20 μL of FITC-conjugated mouse anti-rat CD11b monoclonal 
antibody (BD Pharmingen, San Jose, CA, USA) for 20 min. Negative controls were 
obtained by omitting the antibody. The cells were then washed twice in Hanks buffer and 
centrifuged at 13,500 rpm for 5 min and the pellet was resuspended. The erythrocytes were 
lyzed with a Lysing kit (Biodesign, Saco, ME, USA), after which the cells were washed 
twice again (6,000 rpm, 5 min) and resuspended in 750 μL of Hanks buffer. Computer-
assisted FACStar Plus Becton-Dickinson equipment was used for cytometry; the 
granulocytes were gated on the basis of their characteristic forward and side-scatter 
features. Generally, 10,000 events per sample were collected and recorded; the percentage 
of labeled (activated) granulocytes (relative to the overall marker-bearing cells) and the 
mean fluorescence intensity (average marker density) were calculated [Szabó A 2011] 
 
3.4.3. Leukocyte NADPH-oxidase activity 
The NADPH-oxidase activity of isolated leukocytes was determined by a modified 
chemiluminometric procedure [Bencsik P 2010]. Blood was drawn from the femoral artery 
into EDTA-containing tubes, and the erythrocytes in 100 µL of whole blood were lyzed in 
a hypotonic solution and centrifuged at 2,000 g. The pellet was resuspended and washed 
twice in Dulbecco’s phosphate-buffered saline solution. Twenty µL of resuspended pellet 
was incubated for 3 min at 37 °C in a Dulbecco’s solution containing lucigenin (1 mM), 
EGTA (1 mM) and saccharose (140 mM). NADPH-oxidase activity was determined via the 
NADPH-dependent increase in luminescence elicited by adding 100 mM NADPH (in 20 
µL) with an FB12 Single Tube Luminometer (Berthold Detection Systems GmbH, Bad 
Wildbad, Germany). Samples incubated in the presence of nitroblue tetrazolium served as 
25 
 
controls. The measurements were performed in triplicates and were normalized for protein 
content. 
 
3.4.4. Free radical-producing capacity of the blood 
10 µL of blood dissolved in Hanks buffer was incubated for 20 min at 37 °C in lucigenin (5 
mM; dissolved in Hanks buffer) or luminol (15 mM; dissolved in Hanks buffer) solutions 
in the presence or absence of zymozan (190 µM, dissolved in Hanks buffer). Superoxide 
and hydrogen peroxide productions were estimated via the rate of zymozan-induced 
increase in chemiluminescence (measured with the above luminometer) and normalized for 
leukocyte counts in the peripheral blood. 
 
3.4.5. Plasma TNF-alpha levels 
Blood samples were centrifuged at 13,500 rpm for 5 min at 4 °C and then stored at -70 °C 
until assay. Plasma TNF-alpha concentration were determined in duplicate by means of a 
commercially available enzyme-linked immunosorbent assay kit (R&D Systems, 
Minneapolis, MN, USA). 
 
3.5. Assessment of morphological changes 
3.5.1. Detection of gingival healing processes 
Healing of the gingiva at the end of the study period (6 weeks after the tooth extraction) 
was determined on the basis of the osteonecrosis staging system provided by the American 
Association of Oral and Maxillofacial Surgeons [Ruggiero SL 2014]; this was adapted for 
rats (see Table 2). The examination was performed under an operating microscope (6x 
magnification; Carl Zeiss GmbH, Jena, Germany) by an independent maxillofacial surgeon. 
The incidence and the severity of the gingival healing disorder were evaluated 
simultaneously. 
 
Score Exposed bone Inflammation/infection Fistula formation 
Score 0 - - - 
Score 1 + - - 
Score 2 + + - 
Score 3 + + + 
 
Table 2. Scoring of macroscopic signs of the BIS-related healing processes after tooth extraction 
(adopted from the staging of MRONJ by Ruggiero et al. [Ruggiero SL 2014]) 
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3.5.2. Detection of osteonecrosis through the use of microCT 
Mandibles fixed with formaldehyde were used for micro-CT imaging (SCANCO vivaCT 
75, Scanco Medical, Brüttisellen, Switzerland); subsequent analysis was performed on 2D 
sections in the coronal view of the images, the section being chosen that showed the highest 
degree of tissue defect at the earlier extraction site. The mean density of the bone was 
estimated via the calculated percentage of the radiolucent area of the alveolar portion of the 
bone. 
 
3.5.3. Detection of osteonecrosis through the use of histological analysis 
The specimens were fixed in 6% neutral buffered formalin for 10 days, then rinsed in 
phosphate-buffered saline and decalcified in 5% EDTA for 7 days. The decalcified 
specimens were embedded in paraffin and cut into 20 semi-serial sections with a 
microtome (Shandon Finesse 325, Thermo Scientific, Waltham, MA, USA), and routine 
hematoxylin and eosin (H&E) staining was performed. The sections were examined under 
a light microscope at 4-40x magnification (Modell CHT, Olympos, Hamburg, Germany). 
The incidence of osteonecrosis of the jaw was determined on the basis of characteristic 
signs of necrosis, such as missing nuclear staining, the development of sequester formation 
and inflammatory infiltration. 
 
3.6. Statistical analyses 
The statistical analyses were performed with a statistical software package (SigmaStat for 
Windows, Jandel Scientific, Erkrath, Germany). For the analysis of microcirculatory 
parameters, changes in variables within and between groups (with respect to location and 
treatment, separately) were analyzed by the two-way analysis of varience (ANOVA) test, 
followed by the Holm–Sidak test. Differences between groups (other inflammatory 
parameters, and scores) were analyzed with Student’s t-test. Data are presented as mean 
values and SEM in all Figures and Tables. P values < 0.05 were considered significant. 
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4. RESULTS 
 
4.1. Morphological and functional characteristics of the mandibular and tibial 
periosteal microcirculation 
 With the reported preparation technique, the anterior surface of the tibial periosteum 
provides a larger observation field (ranging between 8.89 and 9.88 mm2) (Figure 3D) than 
that of the exposed mandibular region (ranging between 8.03 and 9.18 mm2) (Figure 3B). 
Furthermore, the entire exposed tibial periosteal surface can be examined by the different in 
vivo microscopic methods, whereas only approximately one third of the mandibular 
periosteum (i.e. its anterior part) can easily be reached by the relatively robust objectives. 
The vascular density reached 0.0182±0.0011/µm in the case of the tibia, and was 
0.0193±0.0008/µm in the mandibular periosteum. The arterioles, capillaries and venules 
can be distinguished on the basis of the vessel diameters and the direction of flow of the 
moving elements (plasma or red blood cells) within them. Within the mandibular 
periosteum, the vascular network consisted mainly of arterioles and venules, but a few 
capillaries and mostly venules were present in the tibial periosteum (as depicted in Figures 
4-6). 
IVM demonstrated that the RBCV values were similar in the two capillary beds 
(827.5±30.1 µm/s in the mandibular and 739.0±37.7 µm/s in the tibial periosteum) (Table 
3). The OPS technique revealed similar RBCV values (data not shown). The IVM data did 
not indicate any significant differences in the magnitude of the leukocyte-endothelial cell 
interactions between the two locations (Table 3). 
 
Periosteum RBCV Rolling Sticking 
Mandible 827.5 ± 30.1 46.6 ± 5.8 13.4 ± 4.4 
Tibia 739.0 ± 37.7 56.9 ± 11.5 18.5 ± 3.9 
 
Table 3. Microcirculatory parameters: RBCV (µm/s) in the capillaries, and PMN rolling (1/mm/s) 
and sticking (1/mm2) in the postcapillary venules of the mandibular and tibial periosteum in rats. 
Mean values ± SEM are presented. 
 
 The CLSM method was applied to stain the cell nuclei of the vascular compartment 
(Figure 6 A,B). The vascular organization was also visualized when intravascular dye 
(FITC-dextran) was employed (Figure 6 C,D). 
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4.2. Periosteal microcirculatory reactions in the mandible in rats treated 
chronically with ZOL 
 IVM recordings of the microcirculation were performed in a mandibular periosteal 
region just adjacent to the site of the earlier tooth extraction and also on the contralateral 
side 6 weeks after tooth extraction. The data were compared with those on the tibial 
periosteum. 
 In vivo microscopy revealed homogenous microvascular perfusion in all of the 
periosteal tissues examined; the RBCVs were similar in the mandibular and tibial capillary 
beds (827.5 ± 30.1 µm/s and 739.0 ± 37.7 µm/s, respectively). The data were similar on the 
two sides of the mandible and were not influenced by chronic ZOL treatment (data not 
shown). 
 However, the leukocyte rolling in the postcapillary venules of the mandible in the 
ZOL-treated group was significantly higher than in the saline-treated group both at the site 
of tooth extraction and on the contralateral side; the differences between the sites were not 
statistically significant (Figure 7). 
 
 
 
Figure 7. Periosteal primary leukocyteendothelial cell interactions (rolling) in saline- and ZOL-
treated animals in the postcapillary venules of the mandible on the tooth extraction (Ex) and the 
contralateral (C) sides and in the tibia. Data are presented as means ± SEM. * P < 0.01 vs the 
corresponding saline-treated group. # P < 0.05 vs the tibia. Two-way ANOVA was followed by the 
Holm–Sidak test. 
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Similar differences were observed in the leukocyte adhesion values after ZOL, which 
revealed a statistically significant enhancement in the mandibular periosteum as compared 
with the tibial periosteum (Figure 8). 
 
 
Figure 8. Periosteal secondary leukocyteendothelial cell interactions (sticking) in the postcapillary 
venules of the mandible on the tooth extraction (Ex) and the contralateral (C) sides and in the tibia 
in saline- and ZOL-treated animals. Data are presented as means±SEM. * P < 0.01 vs the 
corresponding saline-treated group. # P < 0.01 vs the tibia. Two-way ANOVA was followed by the 
Holm–Sidak test. 
 
 ZOL evoked similar rolling and adhesion values irrespectively of the presence of 
MRONJ (data not shown). The tibial microcirculation was characterized by higher 
leukocyte rolling, but similar adhesion in comparison with the data obtained for the 
mandible in the saline-treated animals; none of them were influenced by ZOL at this 
location. 
 
4.3. Gingival and mucosal healing of the mandible in rats treated chronically with 
ZOL  
 Six weeks after the tooth extraction, intact mucosa could be observed in 8/10 of the 
control animals (the average healing score was 0.25 ± 0.25), but different degrees of 
mucosal healing disorders were detected in all (10/10) of the ZOL-treated animals. The 
severity of the healing disorders reached a score of 1.83 ± 0.18 in this group (P < 0.01). 
 Normal bony regeneration with a radiolucent areas of 12.09 ± 1.91% of the alveolar 
bone could be detected at the site of the earlier tooth extraction in all (10/10) of the saline-
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treated animals. In contrast, a certain degree of discontinuity of the cortical and spongious 
bone regions was found in 7/10 of the ZOL-treated animals. This higher incidence of 
impaired bony regeneration was accompanied by a significantly lower average bone 
density in this group (39.51 ± 7.18% of the alveolar area) as compared with that in the 
saline-treated group (P < 0.01) (Figure 9). 
 
A      B            C 
 
Figure 9. Bone density differences expressed as a percentage of the radiolucent area of the alveolar 
bone (marked with a rectangle) in saline- and BIS-treated animals 6 weeks after tooth extraction 
(section A). Data are presented as means ± SEM. * P < 0.05 vs saline, Student’s t-test. Micro-CT 
scans show representative images of the mandibular cross-sections in saline- and ZOL-treated rats 
(sections B and C, respectively). 
 
The radiological diagnosis of mandibular osteonecrosis was confirmed by standard 
histological examinations (Figure 10). Findings of missing nuclear staining in the 
osteocytes, increased inflammatory infiltration and granulation tissue formation around the 
necrotic area, and occasional sequester formation were made in 6/10 of the ZOL-treated 
animals, whereas nearly normal bone regeneration was observed in the other rats. 
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Figure 10. Representative micrograph (H&E staining) showing regeneration processes in a ZOL-
treated animal 6 weeks after tooth extraction (magnification 4x) (section A). s: salivary gland, m: 
muscle b: bone, g: gingiva, ct: connective tissue. Sequester formation (se) and lack of nuclear 
staining of the necrotic bone (nb), and PMN granulocyte infiltration around the necrotic area (center 
of the section) can be seen at higher magnifications (magnifications 10x and 40x) (sections B and 
C, respectively). The bar denotes 200 µm. 
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4.4. Consequences of chronic ZOL treatment on systemic inflammatory parameters  
To exclude the possibility of increased leukocyte counts behind the increased PMN rolling 
and adhesion after ZOL treatment, the number of PMNs was determined with the 
conventional Türk solution staining method and using a hemocytometer 6 weeks after tooth 
extraction. As expected, the number of PMNs was not higher (but rather even lower) in the 
rats chronically treated with ZOL (Table 4). 
 
Parameter Saline ZOL P values 
PMN count in the blood (cells/µL) 4513 ± 250 3731 ± 215 < 0.05 
CD11b expression (mean fluorescence intensity) 1.57 ± 0.21 1.37 ± 0.09 n.s. 
TNF-alpha (pg/mL) 2.65 ± 0.49 2.33 ± 0.39 n.s. 
 
Table 4. The effects of chronic ZOL treatment on the leukocyte count, neutrophil-derived CD11b 
adhesion molecule expression and plasma TNF-alpha levels. Data are presented as mean ± SEM. P 
< 0.05 vs saline, Student’s t-test. 
 
As evidenced by the mean fluorescence values of the adhesion molecule CD11b 
within the leukocyte population (as measured by flow cytometry), no significant 
differences was detected between the saline- and ZOL-treated animals (Table 4). There 
were no differences between the saline- and ZOL-treated experimental groups with respect 
to the plasma TNF-alpha levels either (n=6 and n=5, respectively) (Table 4). 
The NADPH-oxidase activity of the neutrophil leukocytes harvested from the ZOL-
treated animals was significantly lower than that for the control animals (Figure 11A). The 
free radical-derived chemiluminescence of the whole blood (as determined by the 
superoxide and hydroxyl radical-dependent chemiluminescence measurements) indicated 
no differences between the two experimental groups (Figure 11B). 
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A                 B 
 
 
Figure 11. The effects of chronic ZOL treatment on leukocyte NADPH-oxidase activity (A) and 
whole blood free radical production (B) (the latter shown by chemiluminescence in the presence of 
lucigenin and luminol to detect superoxide anion and hydroxyl radical production, respectively). 
Data are presented as means ± SEM. * P < 0.05 vs saline, Student’s t-test. 
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5. DISCUSSION 
 
5.1. The importance of mandibular periosteal microcirculatory examinations in 
various maxillofacial diseases 
As a major source of osteoprogenitor cells, the periosteum of the jaw bones has a 
high impact in the pathogenesis of various orofacial diseases, but specific, real-time 
examination of its microcirculation can be performed only after surgical exposure of this 
structure. As a result, the periosteal microcirculation has been examined in only a relatively 
limited number of studies of the tibia [Rücker M 1998, Schaser KD 2003, Zhang L 2003, 
Varga R 2008] or the calvaria [Stuehmer C 2009], and we are aware of only one study in 
the maxilla-mandibular region, in rabbits [Rücker M 2005]. All of these latter studies 
involved the use of conventional fluorescence IVM which (as opposed to OPS) also makes 
possible the investigation of microcirculatory perfusion, permeability and leukocyte–
endothelial interactions. In Study 1, we developed a surgical approach to the mandibular 
periosteum. When a rodent model is to be established, similarities to the human anatomy 
should first be ascertained. The most accessible region, where the periosteum is situated 
most superficially, is the area medial to the parotideomasseteric region [Cox PG 2011]. 
This region, between the superficial masseter muscles and the mentum, just laterally to the 
ever-growing incisor tooth of the rat, can be approached by incising the skin and 
subcutaneous tissue. We gained access to the periosteum next to the anterior part of the 
superficial masseter muscle in the area where this muscle adheres to the ventral margin of 
the mandible. It was considered important to proceed laterally to the continuously growing 
incisor teeth so as to avoid any potential functional dissimilarities to the human 
characteristics.  
 The fluorescence IVM data revealed that the mandibular microcirculatory variables 
are similar to those seen in the tibia. It should be added that the preparation was stable for 
approximately 4 h in preliminary experiments, when only IVM was employed (data not 
shown). In the case of CLSM, the potential toxic effects of topically-applied nuclear dyes 
would probably influence the microcirculation in the long run, and examination may 
therefore preferably be restricted to one time point only. As regards the periosteal 
microcirculation, examination of the effects of surgical trauma of the tibia [Zhang L 2003] 
and the maxilla [Rücker M 2005] is a possible target for IVM methods. Such questions can 
also be answered by using the present exposure technique. Moreover, the consequences of 
tooth extraction (particularly of first molars) and the subsequent osteogenesis on the 
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periosteal microcirculatory reactions may also be examined. In previous studies, 
osteogenesis-related capillary density changes (by OPS) [Lindeboom JA 2008] and 
leukocyte–endothelial interactions in experimental peridontitis (by IVM) [Carvalho RR 
2009] were examined in the mucosa, but never in the periosteum. Furthermore, the present 
model appears suitable for CLSM; the penetration of intranuclear dyes for the examination 
of angiogenesis and apoptosis is also possible. CLSM has previously been employed in the 
oral mucosa to visualize intraoral mucosal lesions, tumors [Franz M 2007], borders of 
malignancies and resection margins [Capodiferro S 2008, Scivetti M 2009, Haxel BR 
2010]. 
 The IVM approach can be a particularly valuable tool for the examination of oral 
inflammatory processes. In consequence of the relatively high penetration depth of laser 
light, laser-Doppler flowmetry has been used for the detection of mucosal/gingival 
inflammatory processes. As examples, the consequences of periodontal access flap surgery 
and inflammation have been detected in the gingiva [Kerdvongbundit V 2003, Retzepi M 
2007] and in the pulpar blood flow [Verdickt GM 2001]. With use of the proposed method, 
such inflammatory complications could also be examined by using the mandibular 
periosteum. 
 Study 1 demonstrated certain differences in architecture in the mandibular and the 
tibial periosteum. Specifically, the venules proved to be the predominant structures in the 
examined anteromedial surface of the tibia, whereas arterioles were also detected in the 
mandible. Differences within the skeletal system were earlier reported, when it was found 
that the jaw microcirculation has a higher number of anastomoses and a greater impact of 
the centromedullar circulation as opposed to the long bones of the skeleton [Chanavaz M 
1995]. A corrosion cast study similarly revealed lower numbers of capillaries and arterioles 
in the periosteal compartment than in the gingival compartment, which is characterized by 
a rich capillary network [Nobuto T 1989]. At the present stage, the impact of our 
observations cannot be fully assessed and potential regional differences should also be 
taken into account: we earlier demonstrated [Greksa F 2012] that the anterolateral side of 
the tibia (which has been used in a myocutaneous flap model [Rücker M 1998]) has more 
capillaries than on the anteromedial side. We consider that the higher density of venules 
may predispose to microcirculatory inflammatory complications, e.g. the transmigration of 
neutrophil leukocytes through the postcapillary venules. 
 In summary, the new microsurgical approach presented provides access to the 
periosteal microcirculation in the rat mandible. We compared the mandibular 
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microcirculatory variables with those of a standard and stable tibial model by using 
fluorescence IVM to ascertain that this new technique does not cause microcirculatory 
disturbances or inflammatory complications. It was demonstrated that this exposure 
procedure makes the mandibular periosteum accessible for OPS and CLSM examinations. 
It is anticipated that this model and the investigation of mandibular microcirculatory 
alterations may contribute to a better understanding of maxillofacial or dentoalveolar 
diseases. 
 
5.2. Periosteal microcirculatory inflammatory processes playing a potential role in 
the pathogenesis of MRONJ 
 In Study 2, via the chronic administration of high i.v. doses of ZOL in combination 
with an invasive dental intervention, a high prevalence of mucosal healing disorders (~ 
100%) was achieved together with a relatively high osteonecrosis rate (70%; as revealed by 
micro-CT and histological analyses). This protocol was based on a modified literature 
method [Biasotto M 2010]. BIS doses in the range 20-2250 µg/kg with different 
frequencies and different administration routes have been administered by others (for a 
meta-analysis, see Barba-Recreo P 2013). The relatively high dose applied here (80 
µg/kg/week) is still well tolerated in rats and, although it was also administered in a higher 
frequency than on human use, it produced symptoms and radiological evidence similar to 
those observed in humans. Apart from the dose of ZOL, the relatively high incidence of 
MRONJ in this study can be explained by the triggering effect of the applied dental 
extraction (the importance of which has been demonstrated in MRONJ patients) [Ruggiero 
SL 2014]), and the use of the mandibular site (there is a higher prevalence of osteonecrosis 
at this localization in humans) [Marx RE 2007]. 
 It is reasonable to assume that impaired regeneration processes contribute to the 
pathophysiology of MRONJ. From a functional aspect, bony regeneration processes depend 
not only on the functional activity of the osteoblasts and osteoclasts, but also on the blood 
supply and angiogenesis. BISs have been shown to influence all of these processes. As 
such, the inhibition of osteoclast recruitment to the bone surface [Rodan GA 1996] and 
shortening of the osteoclast life span are the main effects of BISs that are brought about 
directly or indirectly (via the osteoprotegerin-RANKL pathway) [Maruotti N 2012]. 
Accordingly, delayed bone healing [Kobayashi Y 2010, Yamashita J 2011], together with 
decreased bone formation and vascularity in the extraction socket, have been detected in 
ZOL-treated rats [Aguirre JI 2012]. Numerous studies have elucidated the antiangiogenic 
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effects of BIS both in vitro [Wood J 2002] and in vivo [Kobayashi Y 2010, Pabst AM 
2014]. Furthermore, thicker and less connected/ordered blood vessels in the alveolar bone 
of the mandible were found in ZOL-treated rats after tooth extraction [Guevarra CS 2013].  
The periosteum contains a population of stem/osteoprogenitor cells playing key 
roles in bone repair [Brighton CT 1992, Allen MR 2004, Xie C 2008, Chappuis V 2012]. 
BISs bound to a bone surface can affect adjacent cells and inhibit their growth [Cornish J 
2011]. A critical concentration of BIS in the mandible [Kimmel DB 2007, Reid IR 2007, 
Wen D 2011], and the direct toxic and related inflammatory effects in the periosteum may 
also contribute to the development of MRONJ. BISs exert toxic effects on many different 
cell types (fibroblasts, osteoblasts, and endothelial and epithelial cells), manifested in 
diminished cell proliferation and decreased collagen production, ZOL being the most 
inhibitory in this respect [Reid IR 2007, Naidu A 2008, Scheper MA 2009, Agis H 2010, 
Açil Y 2012]. 
 Marked inflammatory reactions are attributed to BISs through the induction of 
peritonitis via the activation of immunological pathways after i.p. administration 
[Calligeros D 1993, Yamaguchi K 2000, Norton JT 2011]. Enhanced leukocyte–endothelial 
interactions have been demonstrated by means of IVM after BIS treatment in an arthritis 
model in mice [Zysk SP 2003]. BIS-associated inflammatory bony changes have also been 
detected in the mandible [Senel FC, 2010]. Interestingly, these inflammatory changes were 
limited to the mandible, and were not seen in the femur or the tibia [Senel FC 2010, Yu YY 
2012]. High-dose ZOL exacerbates the inflammatory response in a periodontitis model, 
where the bone lesions strikingly resemble MRONJ [Aguirre JI 2012]. In the present study, 
pro-inflammatory aspects of chronic BIS treatment could also be traced in the mandibular 
periosteum, and histological analysis supported the infiltration of the tissue by leukocytes 
in the neighboring necrotic zone. 
In this microsurgical model, the periosteal microcirculation of the mandible can be 
visualized relatively easily in the molar region, which is likewise a cardinal localization of 
MRONJ [Ruggiero SL 2014]. Apart from nutritive considerations, the periosteum is 
important for its osteoprogenitor cell content during bone regeneration.  Although BISs 
exert effects on osteoblast proliferation, differentiation and migration in the entire skeleton 
[Koch FP 2011], their action seems to depend on the anatomical location, with the jaw 
bones as highly frequent sites of osteonecrosis. After prolonged use, BISs are known to 
accumulate in the skeleton, reaching the highest concentration in the mandible [Reid IR 
2007, Wen D 2011], which may explain their potential toxic effects predominantly in the 
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jaw bones. Furthermore, osteoblasts have different proliferation properties at different 
locations (appendicular vs axial bones) under physiological circumstances, and this 
phenomenon is also critically influenced by BIS treatment [Marolt D 2012]. The functional 
activity of the osteocytes too differs between the mandible and the tibia [Çankaya M 2013], 
and the aggravating effects of BISs on bone healing are confined to the jaw [Kuroshima S 
2014]. Although the above findings reveal certain potential factors contributing to the 
higher incidence of osteonecrosis of the jaw bones, the exact pathomechanism is unknown. 
As opposed to the microcirculatory consequences of bone injury (i.e. fractures) 
[Zhang L 2003], the effects of tooth extraction on the microcirculatory derangement and 
local inflammation are less commonly described, due to methodological constraints. We 
focus here on the microcirculatory aspects of chronic ZOL treatment combined with an 
earlier local trauma of the jaw (tooth extraction). IVM data were obtained in the proximity 
of the injury and from a contralateral (intact) site on the mandibular periosteum and were 
compared with those relating to the intact tibia. After chronic ZOL treatment, increased 
degrees of leukocyte–endothelial interactions (rolling and adhesion) were observed in the 
mandibular periosteum, both at the site of the earlier tooth extraction and at the 
contralateral site, but the corresponding interactions in the tibia were less extensive. It is 
still an unanswered question why the examined cell-to-cell interactions are higher in the 
postcapillary venules of the mandible, irrespectively of the proximity of the tooth 
extraction site and the presence of MRONJ in the ZOL-treated group. In preliminary 
studies, we did not observe inflammatory complications in the mandibular periosteum 
without tooth extraction, which demonstrated the triggering effect of the trauma in this 
region. This observation was supported by further findings, when more intense 
inflammatory reactions of ZOL were evolved in the acute phase after tooth extraction (data 
not shown). The inflammatory processes were similarly shown in an IVM study to be 
aggravated by a BIS in an arthritis model in mice [Zysk SP 2003]. Elevated levels of the 
pro-inflammatory cytokine TNF-alpha have been reported in human patients in response to 
certain types of BISs [Katz J 2011, Anastasilakis AD 2012, Tzermpos F 2013], but were 
not detected after the chronic administration of ZOL in our study. Furthermore, the number 
and functional activity (free radical-producing capacity) of PMNs were moderately reduced 
here. Such effects on the free radical-producing potential of PMNs (including NADPH-
oxidase and myeloperoxidase activity) have also been demonstrated by others [Yamagishi 
S 2005, Salvolini E 2009, Kuiper JW 2012]. It has been suggested that the compromised 
neutrophil functions too may be used as potential biomarkers for MRONJ susceptibility 
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[Favot CL 2013]. Interestingly, others have found impaired neutrophil chemotaxis after 
BIS exposure in mice [Kuiper JW 2012] and humans [Favot CL 2013], and this parameter 
is influenced most extensively by ZOL among the different types of BISs [Hagelauer N 
2014]. For leukocyte-endothelial interactions (as seen in our study), an enhanced 
expression of adhesion molecules is required on the surface of the endothelial cells and/or 
neutrophil leukocytes [Eppihimer MJ 1997].  Interestingly, the expression of the 
neutrophil-derived adhesion molecule CD11b (responsible for leukocyte adherence) was 
not found to be influenced by chronic ZOL treatment here or in other studies. The extents 
of these inflammatory reactions, however, differed in the jaw and the tibial regions. 
Minodronate was reported to inhibit the VEGF-induced expression of intercellular adhesion 
molecule-1 in endothelial cells [Yamagishi S 2004] and a similar finding was revealed by 
local administration of clodronate-liposomes in the synovial lining of rheumatoid arthritis 
patients [Barrera P 2000]. Regional differences might therefore be explained by different 
degrees of endothelium-derived adhesion molecule expression at the different anatomical 
locations. 
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6. SUMMARY OF NEW FINDINGS 
 
1. We have developed a novel microsurgical approach which provides a simple and 
reproducible approach to the mandibular periosteum of the rat, where morphological 
and functional features of the microvasculature can be assessed by different in vivo 
visualization techniques (IVM, OPS and CLSM methods). This access to the 
mandibular periosteum offers an excellent opportunity for investigations of 
microcirculatory manifestations of dentoalveolar and maxillofacial diseases. 
2. Microvascular processes were explored after chronic ZOL treatment for the first time 
in the mandibular periosteum in rats. 
3. Chronic BIS treatment in combination with tooth extraction induced: 
- gingival healing disorders and radiologically determined osteonecrosis in the 
mandible, which resembles the clinical signs of MRONJ; 
- periosteal microcirculatory inflammatory reactions confined to the mandible (not 
present in the tibial periosteum). 
4. Regional differences between the mandibular and tibial periosteum might be explained 
by different degrees of endothelium-derived adhesion molecule expression at the 
different anatomical locations after chronic ZOL treatment. This observation may 
contribute to a better understanding of the pathomechanism and the development of 
strategies to counteract BIS-induced side-effects. 
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ABSTRACT
Objective: The periosteum plays an important role in bone
physiology, but observation of its microcirculation is greatly limited
by methodological constraints at certain anatomical locations. This
study was conducted to develop a microsurgical procedure which
provides access to the mandibular periosteum in rats.
Methods: Comparisons of the microcirculatory characteristics
with those of the tibial periosteum were performed to confirm the
functional integrity of the microvasculature. The mandibular
periosteum was reached between the facial muscles and the anterior
surface of the superficial masseter muscle at the external surface of
the mandibular corpus; the tibial periosteum was prepared by
dissecting the covering muscles at the anteromedial surface.
Intravital fluorescence microscopy was used to assess the leuko-
cyte–endothelial interactions and the RBCV in the tibial and
mandibular periosteum. Both structures were also visualized
through OPS and fluorescence CLSM.
Results: The microcirculatory variables in the mandibular perios-
teum proved similar to those in the tibia, indicating that no
microcirculatory failure resulted from the exposure technique.
Conclusion: This novel surgical approach provides simple access to
the mandibular periosteum of the rat, offering an excellent
opportunity for investigations of microcirculatory manifestations
of dentoalveolar and maxillofacial diseases.
KEY WORDS: mandibular periosteum, intravital microscopy, orthog-
onal polarization spectral imaging, confocal laser scanning micros-
copy, rat
Abbreviations used: CLSM, confocal laser scanning microscopy;
FITC, fluorescein isothiocyanate; i.v., intravenous; IVM, intravital
microscopy; OPS, orthogonal polarization spectral imaging; RBCV,
red blood cell velocity.
Please cite this paper as: Varga R, Janovszky A, Szabo A, Garab D , Bodnar D, Boros M, Neunzehn J, Wiesmann HP, Piffko J. A novel method for in vivo
visualization of the microcirculation of the mandibular periosteum in rats. Microcirculation 21: 524–531, 2014.
INTRODUCTION
The rich blood supply of the maxillofacial region ensures fast
healing of the tissues in the oral cavity. On the other hand,
these tissues, and the bones of the jaw in particular, are
strikingly prone to local inflammatory complications, rang-
ing from abscess formation to osteomyelitis and osteonecro-
sis [30]. It is reasonable to assume that functional and
morphological impairments of the periosteal microcircula-
tion are critically involved in these processes. This assump-
tion is supported by clinical observations where
osteonecrosis and defective angiogenesis of the mucoperio-
steal tissues were demonstrated in patients receiving chronic
bisphosphonate treatment [37]. In general, the role of the
periosteal integrity in bone physiology is well recognized, not
only as it concerns to the maintenance of the vascular supply
but also from the aspect of active regulation of the bone
metabolism and regeneration. It is similarly well known that
successful healing after fractures requires the regeneration of
the peri- and endosteal circulations [20]. It follows that
periosteal microvascular alterations can be of importance in
the pathomechanism of oral diseases associated with a
deterioration of tissue perfusion and with inflammatory
complications.
The vascular architecture of the intraoral region, including
the periosteum, can be examined by imaging methods such
as computer tomography, magnetic resonance imaging and
to some extent scintigraphy or histology [3,4,11,23]. Never-
theless, these tools are not relevant when dynamic changes or
functional aspects of the periosteal microcirculation are to be
DOI:10.1111/micc.12128
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investigated. The methods utilized for examinations of the
functional characteristics of the microcirculation, such as
hemoglobin absorptiometry combined with laser-Doppler
flowmetry, may provide information on tissue oxygenation
and perfusion, but in this case the tissue mass is rather
robust, e.g., the gingiva [21]. If more accurate detection or
improved spatial resolution of the microcirculation is
needed, fluorescence IVM can provide an opportunity for
real-time examination of the microcirculation of superficial
layers of different organs. Conventional fluorescence IVM
has many advantages. It can visualize not only changes in the
efficacy of microvascular perfusion but also leukocyte–
endothelial interactions, metabolic variables, or signs of
apoptosis [1,17]. For observation of the microcirculation of
superficial tissue layers, nonfluorescence techniques such as
OPS [14] and sidestream dark-field imaging have also been
developed [22]. These methods have the advantage that the
use of fluorescence markers is not necessary and this allows a
possibility for human applications also in the oral cavity
[10,22]. Observation of the periosteal compartment would
still necessitate surgical exposure, but the imaging of
individual vessels and cells is possible without disturbing
their functional characteristics.
The calvarian periosteum can be visualized in experimen-
tal settings [32], but examination of the microcirculation of
the jaw bones runs into many technical difficulties. We
earlier developed methods suitable for visualization of the
tibial periosteum and the synovial membrane in the knee
joint in rats [15,34], but such approaches were not available
for the exposure and in vivo investigation of the mandibular
periosteum. We therefore considered it important to address
this issue, in part to solve the technical problems and in part
because the physiology or the pathophysiological reactions of
the jaw may differ from those in other bones of the skeleton.
Specifically, bisphosphonates have been demonstrated to
cause osteonecrosis in the jaw after invasive dental proce-
dures, but such reactions do not occur in the bones of the
appendicular skeleton [5,31]. This observation suggests that
potentially different microcirculatory reactions may evolve in
the periosteum at different anatomical locations. For this
reason, we set out to compare the microcirculatory charac-
teristics of the mandibular and the tibial periosteum through
the use of a microsurgical approach and microscopic
methods that are suitable for in vivo visualization of
individual microvessels. Firstly, the functional integrity of
the mandibular microcirculation was ascertained by using
the OPS method, where the use of fluorescent markers is not
required (and sampling for biochemical and molecular
biological analyses is therefore possible). We used the “gold
standard” fluorescence IVM for the determination of perfu-
sion and leukocyte–endothelial interactions. Finally, CLSM
was chosen as it offers an opportunity for determination of
the in vivo histology of tissues (including microvessels)
without sectioning, fixation, and embedding artifacts. The
final aim of the study was to provide a comprehensive
methodological basis for future investigations targeting the
potential microcirculatory manifestations of oral diseases.
MATERIALS AND METHODS
The experiments were performed in full accordance with the
NIH Guidelines (Guide for the Care and Use of Laboratory
Animals) and approved by the Animal Welfare Committee of
the University of Szeged (V/1639/2013).
Animals
Ten male Sprague–Dawley rats were used (the average weight
at the time of the experiment was 320  10 g). The animals
were anaesthetized intraperitoneally with an initial dose of
sodium pentobarbital (45 mg/kg). After cannulation of the
trachea, the penile vein was cannulated to administer fluids
and drugs (supplementary dose of sodium pentobarbital;
5 mg/kg). During preparation and microcirculatory investi-
gations, the rats were placed in a supine position on a heating
pad to maintain the body temperature at 36–37°C.
Surgical Procedures
The fur of the animals in the mandibular region was shaved,
and a lateral incision parallel to the incisor tooth was made in
the facial skin and the underlying subcutaneous tissue using a
careful microsurgical approach under an operating micro-
scope (69 magnification; Carl Zeiss GmbH, Jena, Germany).
The masseter muscle consists of superficial and deep parts, the
latter being further divided into anterior and posterior
sections in rats [9]. The fascia between the anterior part of
the deepmasseter and the anterior superficial masseter was cut
with microscissors (Figure 1A). By this means, the periosteal
membrane covering the corpus of the mandible laterally to the
incisor tooth was reached and it was gently separated from the
covering thin connective tissue (Figure 1B). Stitches with 7.0
monofilament polypropylene microsurgical thread were
placed into the surrounding masseter muscles for retraction
and better exposure of the region of interest. We applied this
surgical approach on both sides of the lower jaw. With this
preparation technique, the periosteal microcirculation of the
mandible could be examined by in vivo microscopic methods
at the anterior margin of the molar region.
For comparison of the characteristics of the mandibular
microcirculation with those of the tibial periosteum, the
medial/anterior surface of the tibia was exposed by complete
transection of the anterior gracilis muscle with microscissors,
and careful atraumatic microsurgical removal of the con-
nective tissue covering the tibial periosteum (Figure 1C,D)
[34]. These dissections were performed on both sides to
permit parallel observations of intravascular and topically
applied fluorescence tracers (see later).
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Experimental Protocol
After surgical exposure of the mandibular and tibial perios-
teum on both sides, recordings were performed on the right
side with OPS, which does not require any fluorescence
labeling (see later) (Figure 2A,B). After this, the animals
received i.v. injections of FITC-labeled erythrocytes (0.2 mL;
Sigma Aldrich, St. Louis, MO, USA) (Figure 3A,B) [27] and
rhodamine-6G (0.2%, 0.1 mL; Sigma Aldrich) for the
staining of leukocytes (Figure 3C,D), and IVM recording
was performed at the previous locations. Subsequently,
50 lL of the nuclear dye acriflavin (1 mM) was applied
topically to the tibial periosteal surface on the left side and
was rinsed off with warm physiological saline solution after
an exposure time of one minute, and then CLSM recording
was performed (Figure 4B). The same staining procedure
was carried out for the mandible on the left side (Figure 4A).
This was followed by an i.v. injection of the plasma dye
FITC-dextran 150 kDa (i.v. 0.3 mL, 20 mg/mL solution
dissolved in saline; Sigma Aldrich), and CLSM (Figure 4C,D)
and IVM recordings (Figure 3E,F) were made on the tibia
and the mandible on the right side five minutes after
injection of the tracer.
OPS Technique
The exposed periosteum of the corpus of the mandible or the
tibial periosteum on the right side was horizontally posi-
tioned on an adjustable stage and superfused with 37°C
saline. The periosteal membranes were first visualized with
A B
DC
Figure 1. Exposure of the mandibular and
tibial periosteum for in vivo microscopic exam-
inations. Access to the mandibular periosteum
was achieved by making a lateral incision
parallel to the incisor tooth in the facial skin
and the underlying subcutaneous tissue, which
was followed by gentle separation of the fascia
between the anterior part of the deep masse-
ter (dm) and the anterior superficial masseter
(asm) muscles (A, B). Finally, the thin connec-
tive tissue covering the periosteum was gently
incised with microscissors. By this means, the
periosteal membrane covering the corpus of
the mandible laterally to the incisor tooth was
reached. The tibial periosteum was reached by
transecting the anterior gracilis (ag) muscle
completely in the middle (and a part of the
posterior gracilis muscle [pg] too) and gently
removing the thin connective tissue covering
the periosteum (C, D). The bar denotes
2500 lm.
A B
Figure 2. Micrographs showing the mandib-
ular (A) and tibial periosteum (B) made with
the OPS technique. The bar denotes 200 lm.
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an OPS device (CytoscanTM; Cytometrics, Philadelphia, PA,
USA), which provides optimal imaging of the microvascular
structures at a chosen focus level [penetration depth: approx.
200 lm; 11] (Figure 2A,B). This technique utilizes epi-
illumination with linearly polarized light at 548 nm (which is
the isobestic point of oxy- and deoxyhemoglobin) to
visualize hemoglobin-containing structures without the
additional use of a fluorochrome. Images were recorded on
a SVHS video recorder (Panasonic AG-MD 830; Matsushita
Electric Industrial Co., Tokyo, Japan) and a personal
computer.
Fluorescence IVM
The periosteal microcirculation was visualized by IVM
(penetration depth: approx. 250 lm; Zeiss Axiotech Vario
100HD microscope; 100-W HBO mercury lamp; Acroplan
209 /0.5 N.A. W; Carl Zeiss GmbH, Jena, Germany). Images
from three–four fields of the mandibular and the tibial
periosteum (Figure 3) were recorded with a charge-coupled
device video camera (Teli CS8320Bi; Toshiba Teli Corpora-
tion, Osaka, Japan) attached to an S-VHS video recorder
(Panasonic AG-MD 830; Matsushita Electric Industrial Co.)
and a personal computer (see labeling techniques above).
Fluorescence CLSM
Confocal imaging of the surface of the mandibular and tibial
periosteum was performed with a Five1 Optiscan device
(Optiscan Pty. Ltd., Melbourne, Vic., Australia) (Figure 4).
In vivo histology was employed by placing the Optiscan
probe on the surface of the periosteal membranes and by
changing the focus level through virtual sections of 7 lm
during the confocal imaging (penetration depth: 0–250 lm).
Cell nuclei were first stained with topically applied acriflavin
(see above) on the left side, and this was followed by
recordings on the contralateral side after i.v. injection of the
intravascular tracer FITC-dextran (see above). Images were
stored on a personal computer provided by the manufac-
turer.
Video Analysis
Quantitative evaluation of the microcirculatory parameters
was performed off-line by the frame-to-frame analysis of the
A B
C D
E F
Figure 3. Fluorescence intravital microscopic
images of the mandibular (A, C, E) and the
tibial periosteum (B, D, F), involving
FITC-labeled erythrocytes (A, B), rhodamine
6G-labeled neutrophil leukocytes (C, D), and
FITC-dextran-labeled plasma (E, F). The bar
denotes 200 lm.
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videotaped images taken for IVM and OPS (IVM Software;
Pictron Ltd, Budapest, Hungary). Leukocyte–endothelial cell
interactions were analyzed at least in four postcapillary
venules per rat. Rolling leukocytes were defined as cells
moving with a velocity less than 40% of that of the
erythrocytes in the centerline of the microvessel and passing
through the observed vessel segment within 30 seconds, and
are given as the number of cells per second per vessel
circumference. Adherent leukocytes were defined as cells that
did not move or detach from the endothelial lining within an
observation period of 30 seconds and are given as the
number of cells per mm2 of endothelial surface, calculated
from the diameter and length of the vessel segment. RBCV
(lm/s) was determined by frame-to-frame analysis of 5–6
consecutive video-captured images taken after labeling of the
erythrocytes (see above).
Statistical Analysis
The statistical analysis was performed with a statistical
software package (SigmaStat for Windows, Jandel Scientific,
Erkrath, Germany). Within the IVM data, RBCV values in
the capillaries and the extents of rolling and adherence of
leukocytes in the postcapillary venules of the mandibular and
tibial periosteum were compared by using the Student’s
t-test. Comparisons within the RBCV values measured with
IVM and OPS were also made with the Student’s t-test. p
values <0.05 were considered significant.
RESULTS
With the reported preparation technique, the anterior
surface of the tibial periosteum provides a larger observation
field (ranging between 8.89 and 9.88 mm2) (Figure 1D) than
that of the exposed mandibular region (ranging between 8.03
and 9.18 mm2) (Figure 1B). Furthermore, the entire exposed
tibial periosteal surface can be examined by different in vivo
microscopic methods, whereas only approximately one third
of the mandibular periosteum (i.e., its anterior part) can
easily be reached by the relatively robust objectives. The
vascular density reached 0.0182  0.0011/lm in case of the
tibia and was 0.0193  0.0008/lm in the mandibular
periosteum. The arterioles, capillaries, and venules can be
distinguished on the basis of vessel diameters and the
direction of flow of moving elements (plasma or red blood
cells) within them. Within the mandibular periosteum, the
vascular network consisted mainly of arterioles and venules,
but a few capillaries and mostly venules were present in the
tibial periosteum (as depicted in Figures 2–4).
IVM demonstrated that the RBCV values were similar in
the two capillary beds (827.5  30.1 lm/s in the mandibular
A B
C D
Figure 4. Confocal laser scanning microscopic
images of the mandibular (A, C) and tibial
periosteum (B, D). Cell nuclei were labeled by
the topical application of acriflavin (left side)
(A, B). Images were also taken at both struc-
tures on the right sides after the i.v. injection of
FITC-dextran (C, D). The bar denotes 200 lm.
R. Varga et al.
528 ª 2014 John Wiley & Sons Ltd
and 739.0  37.7 lm/s in the tibial periosteum) (Table 1).
The OPS technique revealed similar RBCV values (data not
shown). The IVM data did not indicate any significant
differences in the magnitude of the leukocyte–endothelial cell
interactions between the two locations (Table 1).
The CLSM method was applied to stain the cell nuclei of
the vascular compartment (Figure 4A,B). The vascular
organization was also visualized when intravascular dye
(FITC-dextran) was employed (Figure 4C,D).
At the end of the experiments, tissue specimens were
harvested for histology. The tibial periosteum appeared to be
more strongly attached to the underlying bone than that in
the mandible.
DISCUSSION
Studies of the microcirculation in the oral region gained
considerable attention when the predictive value of mucosal
perfusion deficits was demonstrated in septic shock patients
[33,35]. Another intraoral manifestation of a systemic
menace was revealed during cardiac surgery [2] and the
intraoral microcirculation was demonstrated to correlate well
with the gastrointestinal perfusion changes [35]. The perio-
steal microcirculatory aspects of systemic and intraoral
diseases, however, have been far less well clarified. These
above human observations became possible by the develop-
ment of methods which provide quantitative information on
individual vessels without the need for the use of fluorescent
tracers (i.e., OPS or sidestream dark-field methods). High
spatial resolution is an advantage of intravital microscopic
methods in general, but the relatively low penetration depth
restricts the examination to the superficial layers such as the
mucosal or gingival/mucosal surfaces in the oral cavity.
As a major source of osteoprogenitor cells, the periosteum
of the jaw bones has a high impact in the pathogenesis of
various orofacial diseases, but specific, real-time examination
of its microcirculation can be performed only after surgical
exposure of this structure. As a result, the periosteal
microcirculation has been examined in only a relatively
limited number of studies of the tibia [26,28,34,38] or the
calvaria [32], and we are aware of only one study in the
maxilla–mandibular region, in rabbits [25]. All these latter
studies involved the use of conventional fluorescence IVM
which (as opposed to OPS) also makes possible the
investigation of microcirculatory perfusion, permeability,
and leukocyte–endothelial interactions. In this study, we
developed a surgical approach to the mandibular periosteum.
When a rodent model is to be established, similarities to the
human anatomy should first be ascertained. The most
accessible region, where the periosteum is situated most
superficially, is the area medial to the parotideomasseteric
region [9]. This region, between the superficial masseter
muscles and the mentum, just laterally to the ever-growing
incisor tooth of the rat, can be approached by incising the
skin and subcutaneous tissue. We gained access to the
periosteum next to the anterior part of the superficial
masseter muscle in the area where this muscle adheres to the
ventral margin of the mandible. It was considered important
to proceed laterally to the continuously growing incisor teeth
so as to avoid any potential functional dissimilarities to the
human characteristics.
The fluorescence IVM data revealed that the mandibular
microcirculatory variables are similar to those seen in the
tibia. It should be added that the preparation was stable for
approximately four hours in preliminary experiments, when
only IVM was employed (data not shown). In the case of
CLSM, the potential toxic effects of topically applied nuclear
dyes would probably influence the microcirculation in the
long run, and examination may be therefore preferably be
restricted to one time point only. As regards the periosteal
microcirculation, examination of the effects of surgical
trauma of the tibia [38] and the maxilla [25] is a possible
target for IVM methods. Such questions can also be answered
by using the present exposure technique. Moreover, the
consequences of tooth extraction (particularly of first
molars) and the subsequent osteogenesis on the periosteal
microcirculatory reactions may also be examined. In previ-
ous studies, osteogenesis-related capillary density changes (by
OPS) [19] and leukocyte–endothelial interactions in exper-
imental peridontitis (by IVM) [7] were examined in the
Table 1. Microcirculatory parameters: RBCV in the capillaries, and leukocyte rolling, and sticking in the postcapillary venules of the mandibular and
tibial periosteum in rats as determined by the OPS technique and fluorescence IVM
Method OPS
IVM
Parameter RBCV (lm/s) RBCV (lm/s) Rolling (/mm/s) Sticking (/mm2)
Mandible 736.6  26.7 827.5  30.1 46.6  5.8 13.4  4.4
Tibia 723.7  39.2 739.0  37.7 56.9  11.5 18.5  3.9
Mean values  SEM are presented.
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mucosa, but never in the periosteum. Furthermore, the
present model appears suitable for CLSM; the penetration of
intranuclear dyes for the examination of angiogenesis and
apoptosis is also possible. CLSM has previously been
employed in the oral mucosa to visualize intraoral mucosal
lesions, tumors [12], borders of malignancies, and resection
margins [6,16,29].
The jaws are particularly prone to inflammatory complica-
tions (e.g., periodontitis or abscess), as they can be sensitively
exposed to the external environment in the immediate vicinity
of the teeth. The IVM approach can be a particularly valuable
tool for the examination of oral inflammatory processes. In
consequence of the relatively high penetration depth of laser
light, laser-Doppler flowmetry has been used for the detection
of mucosal/gingival inflammatory processes. As examples, the
consequences of periodontal access flap surgery and inflam-
mation have been detected in the gingiva [18,24] and in the
pulpar blood flow [36]. With use of the proposed method,
such inflammatory complications could also be examined
using the mandibular periosteum.
This study demonstrated certain differences in architec-
ture in the mandibular and the tibial periosteum. Speci-
fically, the venules are proved to be the predominant
structures in the examined anteromedial surface of the tibia,
whereas arterioles were also detected in the mandible.
Differences within the skeletal system were reported by
Chanavaz, who found that the jaw microcirculation has a
higher number of anastomoses and a greater impact on the
centromedullar circulation as opposed to the long bones of
the skeleton [8]. A corrosion cast study similarly revealed
lower numbers of capillaries and arterioles in the periosteal
compartment than in the gingival compartment, which is
characterized by a rich capillary network [23]. At the
present stage, the impact of our observations cannot be
fully assessed and the potential regional differences should
also be taken into account: We earlier demonstrated [13]
that the anterolateral side of the tibia (which was used for a
myocutaneous flap model by R€ucker et al. [26]) has more
capillaries than on the anteromedial side. We consider that
the higher density of venules may predispose to microcir-
culatory inflammatory complications, e.g., the transmigra-
tion of neutrophil leukocytes through the postcapillary
venules.
In summary, the new microsurgical approach presented
provides access to the periosteal microcirculation in the rat
mandible. We compared the mandibular microcirculatory
variables with those of a standard and stable tibial model by
using fluorescence IVM to ascertain that this new technique
does not cause microcirculatory disturbances or inflamma-
tory complications. It was demonstrated that this exposure
procedure makes the mandibular periosteum accessible for
OPS and CLSM examinations. It is anticipated that this
model and the investigation of mandibular microcirculatory
alterations may contribute to a better understanding of
maxillofacial or dentoalveolar diseases.
PERSPECTIVE
The maxillofacial region is particularly prone to inflamma-
tory reactions. The present rat model using IVM techniques
should be useful in further studies exploring the periosteal
microcirculation, pathophysiological mechanisms of bone
regeneration, dentoalveolar diseases, and drug-related com-
plications such as mandibular osteonecrosis.
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A várható élettartam hosszabbodásával egyre gyakoribbak a különféle reumatológiai és onkológiai megbetegedések, 
amelyek csontszövődményeinek csökkentésére széles körben alkalmaznak különböző per os és intravénás antire-
szorptív hatású készítményeket (például biszfoszfonátok). Ezek a szerek jótékony hatásuk mellett súlyos szövődmé-
nyeket is okozhatnak, ilyen például a ma még nem teljesen tisztázott patomechanizmusú állcsontnecrosis. A szerzők 
célja egy átfogó szakmai tájékoztatás nyújtása a gyógyszer indukálta állcsontnecrosis lehetséges megelőzéséről és terá-
piájáról. A szakirodalmi áttekintés alapján készült dolgozat azokat a szűrőmódszereket ismerteti (előnyeikkel és limi-
tációikkal együtt), amelyek segítségünkre lehetnek a gyógyszer indukálta állcsontnecrosis korai detektálásában. A 
szerzők a legújabb sebészi és adjuváns terápiás irányvonalakat is ismertetik. Megállapítják, hogy a patomechanizmus 
ismeretének hiányában jelenleg még hatékony terápiás modalitás nem áll rendelkezésre, és hangsúlyozzák mind a 
prevenció, mind a terápia során az interdiszciplináris együttműködés szükségességét és annak fontosságát. Jelenleg ez 
tűnik a gyógyszer indukálta állcsontnecrosis elleni leghatékonyabb eszköznek. Or. Hetil., 2014, 155(49), 1960–1966.
Kulcsszavak: antiangiogén terápia, antireszorptív kezelés, biszfoszfonát, osteonecrosis
Current approaches for early detection and treatment of medication-related 
osteonecrosis of jaw
Owing to the increased life expectancy, the incidence of rheumatoid disorders and oncologic cases with bone metas-
tasis has dramatically increased. Despite the beneficial effects of the applied antiresorptive and antiangiogenic drugs 
(e.g. bisphosphonates), serious side effects such as jaw osteonecrosis may also develop. The aim of the authors was to 
summarize present knowledge about the possibilities of prevention and treatment in medication-related osteonecro-
sis of the jaw. Based on literature data, currently used detection methods for medication-related osteonecrosis of the 
jaw (including their advantages and limitations) are summarized. In addition, novel trends of surgical and adjuvant 
therapeutic approaches are also reviewed. The authors conclude that possibilities of prevention and efficacy of thera-
peutic interventions in this disorder are still limited possibly due to an incomplete knowledge of the underlying 
pathomechanism. An interdisciplinary cooperation for prevention and attentive monitoring in order to decrease the 
incidence of iatrogenic oral and maxillofacial complications seems to be particularly important.
 
Keywords: antiangiogenic therapy, antiresorptiv treatment, bisphosphonate, osteonecrosis
Janovszky, Á., Vereb, T., Szabó, A., Piffkó, J. [Current approaches for early detection and treatment of medication-
related osteonecrosis of jaw]. Orv. Hetil., 2014, 155(49), 1960–1966.
(Beérkezett: 2014. október 3.; elfogadva: 2014. október 30.)
Rövidítések 
BIS = biszfoszfonát; BRONJ = (bisphosphonate-related oste-
onecrosis of the jaw) biszfoszfonát indukálta állcsontnecrosis; 
CTX = C-terminális telopeptid; LLLT = (low-level laser thera-
py) alacsony energiájú lézerkezelés; MRONJ = (medication-
related osteonecrosis of the jaw) gyógyszer indukálta állcsont-
necrosis; VEGF = (vascular endothelial growth factor) 
endotheliumeredetű növekedési faktor
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Antireszorptív és antiangiogén gyógyszerek 
hatásai és mellékhatásai. A gyógyszer 
indukálta állcsontnecrosis kockázati 
tényezői
A különböző hatásmechanizmusú antireszorptív hatású 
gyógyszerek, legfőképp a biszfoszfonátok (BIS) megjele-
nése, az osteoporosis és csontmetasztázis kezelésében 
jelentős mértékben javították mind a terápia sikeressé-
gét, mind pedig a betegek életminőségét [1, 2]. Az oste-
oclast-aktivitást gátló hatásukat kihasználva a csontépítő 
folyamatok – az osteoblast-osteoclast egyensúly eltoló-
dásával – kerülnek előtérbe, így mára mindezekben a pa-
tológiás csontelváltozásokkal járó kórképekben a stan-
dard terápia részét képezik [3, 4]. Szemben a 
BIS-kezelésnek a vázrendszer csontjaiban kifejtett jóté-
kony hatásaival, az állcsontokban ellentétes hatású folya-
mat léphet fel, amely osteonecrosis kialakulásához vezet-
het. Egyre több publikáció jelenik meg, hogy nemcsak a 
BIS, hanem más antireszorptív [5] vagy antiangiogén 
[6] hatású készítmények mellett is kialakulhat ez a súlyos 
szövődmény. Ennek megfelelően módosult is az ameri-
kai szakmai ajánlás, amelyben ma már gyógyszer indukál-
ta állcsontnecrosisként (medication-related osteonecro-
sis of the jaw – MRONJ) definiálja ezt a kórállapotot, a 
korábbi biszfoszfonát indukálta állcsontnecrosissal szem-
ben (bisphosphonate-related osteonecrosis of the jaw – 
BRONJ) [4].
Incidenciája kapcsán meglehetősen eltérő adatok ér-
hetők el a nemzetközi szakirodalomban, gyakorisága 
0,019–10% között mozog [4]. Az osteonecrosis gyak-
rabban alakul ki a mandibulában, mint a maxillában (2:1) 
[3], a molaris régió gyakrabban érintett, mint a praemo-
laris, illetve frontalis területek [7], valamint fokozódik a 
kockázat invazív fogászati beavatkozást (fogeltávolítást) 
követően [3, 4]. Befolyással bír a betegség kialakulására 
a kezelés indikációja (alapbetegség: osteoporosis, malig-
nus daganat), a BIS beviteli módja (per os vagy intravé-
nás) és időtartama, fennálló szájüregi betegség (perio-
dontalis vagy periapicalis, gyulladásos folyamat), 
társbetegségek, rossz szájhigiéné, dohányzás [4]. A fő 
problémát az jelenti, hogy ennek a progrediáló, súlyos 
elváltozásnak jelenleg nem ismert ténylegesen effektív 
terápiás megoldása és a nemzetközi ajánlásokban írt ke-
zelési modalitások sem hoznak minden esetben sikert [8, 
9].
Mivel a MRONJ pontos patomechanizmusa egyelőre 
nem ismert, számos kockázati tényező, jelátviteli útvonal 
és mechanizmus etiológiai szerepe felmerült. Az alap- és 
klinikai kutatások többsége főként a BIS indukálta gyul-
ladásos és fertőzéses eredet [10], a lokális toxicitás [11], 
valamint az angiogenesist gátló hatások [12] vizsgálatára 
fokuszál. A patomechanizmus megértését nehezíti, hogy 
osteonecrosis néhány évvel a foghúzást követően is kifej-
lődhet BIS-kezelt páciensekben, ami farmakokinetikai 
tulajdonságaikra vezethető vissza (hosszú felezési idő) 
[3].
Ma több mint 200 millióan szenvednek osteoporosis-
ban, illetve annak különböző szövődményeitől világszer-
te [13]. Németországban nagyjából 8 millió alkalommal 
írtak fel BIS-származékot az elmúlt évben. Magyarorszá-
gon megközelítőleg 1 millió regisztrált, osteoporosisban 
szenvedő betegről tudunk (Magyar Osteoporosis és Oste-
oarthrologiai Társaság). Szintén fokozódik a daganatok 
előfordulási gyakorisága, amelyek csontáttétei kapcsán 
gyakran alkalmaznak BIS-készítményeket [14], illetve az 
angiogenesisgátló biológiai, úgynevezett „target terápi-
ák” is egyre inkább előtérbe kerülnek, ahogy azt a meg-
jelenő publikációk száma is jól mutatja. Amellett, hogy 
egyre bővül az említett gyógyszercsoportok indikációs 
köre, valószínű, hogy a MRONJ prevalenciájában is ha-
sonló tendencia lesz megfigyelhető. A fenti adatok jól 
mutatják, hogy súlyos népegészségügyi problémával áll-
hatunk szemben a későbbiek folyamán, de a komplikáci-
ók direkt és indirekt költségei révén a gazdasági vonatko-
zások sem elhanyagolhatóak. 
Az állcsontnecrosis klinikai tünetei  
és stádiumai
Az „American Association of Oral and Maxillofacial Sur-
geons” 2014-ben publikált, szakmai ajánlása alapján 
MRONJ esete állhat fenn, ha az alábbi kritériumok 
mindegyike igazolható [4]:
–  jelenleg is fennálló, vagy az anamnézisben szereplő an-
tireszorptív vagy antiangiogén kezelés;
–  legalább 8 hete nem gyógyuló, denudált csontfelszín 
vagy intra/extra oralis fistula a maxillofacialis régió-
ban;
–  kizárható a korábbi irradiáció vagy egyértelmű me-
tasztázis az állcsontok területén.
A MRONJ alábbi 5 stádiuma állapítható meg [4]:
1. Rizikócsoport: antireszorptív vagy antiangiogén te-
rápiában (per os vagy intravénás) részesült, tünetmentes 
betegek.
2. Stádium 0: atípusos tünetek (odontológiai ok nél-
kül; corpus mandibulae tompa, a temporomandibularis 
ízületbe sugárzó fájdalma; arcüregfájdalom akár gyulla-
dással és a sinus maxillaris falának elvékonyodásával; 
megváltozott neuroszenzoros funkciók) vagy klinikai 
(fogvesztés krónikus periodontalis betegség nélkül; pe-
riapicalis/periodontalis fistula caries eredetű pulpanecro-
sis nélkül) és radiológiai (alveolaris csonthiány krónikus 
periodontalis betegség nélkül; trabecularis szerkezet 
megváltozása az extractio helyén; osteosclerosis az alve-
olaris régióban; periodontalis ligamentum elvékonyodá-
sa) eltérések klinikailag igazolható osteonecrosis nélkül.
3. Stádium 1: denudált, necroticus csontfelszín vagy 
fistula, lokális gyulladás nélkül, alveolaris régióra lokali-
zált radiológiai eltérésekkel. 
4. Stádium 2: denudált, necroticus csontfelszín vagy 
fistula, bakteriális szuperinfekció és kísérő tünetei (fájda-
lom, erythema, pus), alveolaris régióra lokalizált radioló-
giai eltérésekkel (1. ábra).
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5. Stádium 3: denudált, necroticus csontfelszín vagy 
fistula, fertőzés és a következő tünetek legalább egyike: 
alveolaris régión túlterjedő osteonecrosis (mandibula ba-
sisa, ramus mandibulae, sinus maxillaris, os zygomati-
cus), patológiás törés, oro-cutan/oro-nasalis/oro-antra-
lis fistula, osteolysis (mandibula basisa, sinus alap) (2. 
ábra).
A MRONJ kezelése és progressziójának 
megelőzési lehetőségei
A legújabb nemzetközi szakmai ajánlás alapján, akár csak 
a korábbiban, a MRONJ kezelése stádiumspecifikusan 
történik [4].
–  Stádium 0: nem specifikus tünetek csökkentése (fájda-
lomcsillapítás) és konzervatív fogászati kezelés, a bete-
gek szoros utánkövetése a potenciális progresszió vé-
gett.
–  Stádium 1: fájdalomcsillapítás és antimikrobiális szá-
jöblögető használata (chlorhexidin 0,12%-os oldata).
–  Stádium 2: fájdalomcsillapítás, szisztémás antibioti-
kumkezelés, antimikrobiális szájöblögető (chlorhexidin 
0,12%-os oldata) használata.
–  Stádium 3: sebészi debridement vagy a necroticus áll-
csontrészlet-reszekció antibiotikumkezeléssel egybe-
kötve, illetve a maxillofacialis régió integritásának 
helyreállítása különböző rekonstrukciós módszerekkel 
jöhet szóba. Ezeknek a technikáknak az eredményes-
ségéről még nagyon kevés adat áll rendelkezésünkre 
(3. ábra) [4].
Kiegészítő terápiás lehetőségek
Teriparatid
A teriparatid egy humán rekombináns parathyroid hor-
mon, amelyet Lee írt le először a MRONJ kezelése kap-
csán [15]. Ugyan a vegyület fokozta a csontdenzitást a 
csontképződés révén [16], alkalmazása azonban nem 
haladhatja meg a 2 évet, mivel egyes vizsgálatok szerint 
fokozza az osteosarcoma kialakulásának esélyét. Így 
csontmetasztázisok esetén nem is ajánlott [17]. Más 
szerzők ugyanakkor nem igazolták ezt az összefüggést 
15 éves retrospektív klinikai vizsgálatuk során [18].
Pentoxifillin és α-tokoferol 
Epstein és mtsai 2010-ben publikálták, hogy az antimik-
robiális terápiát pentoxifillinnel és α-tokoferollal kiegé-
szítve 74%-ban csökkenthető a progresszió MRONJ ko-
rai stádiumában [19]. Ennek hátterében valószínűleg a 
pentoxifillin mikrokeringésre kifejtett pozitív és gyulla-
dásos citokinekre gyakorolt gátlóhatása állhat [20], míg 
az α-tokoferol esetében annak antioxidáns hatása eme-
lendő ki [21]. 
Alacsony energiájú lézerkezelés (low-level laser 
therapy – LLLT)
A fentebb említett antibiotikumprofilaxis mellett felme-
rült az LLLT alkalmazásának lehetősége is a MRONJ 
kezelése és megelőzése során egyaránt. Hatásai közül ki-
emelendő sebgyógyulást, angiogenesist, csontregenerá-
ciót, kollagén- és fibroblast-proliferációt elősegítő, tehát 
biostimulatív, valamint fájdalomcsillapító effektusa [22, 
23, 24, 25]. Ezek önmagában is igazolhatják az LLLT 
létjogosultságát a kórkép terápiájában. Scoletta és mtsai a 
MRONJ klinikai lefolyását vizsgálták kiegészítő LLLT-
terápia mellett. Vizsgálatuk alapján az LLLT-kezelés ha-
tására az érintett területen csökkent a seb mérete, vala-
mint az oedema és a fájdalom, illetve a genny és fistulák 
kialakulásának gyakorisága is mérséklődött. Emellett az 
sem elhanyagolható tény, hogy a betegek az LLLT-keze-
léseket jól tolerálták [26].
Ózonterápia és hyperbaricus oxigénterápia
Agrillo és mtsai retrospektív klinikai tanulmányukban be-
számoltak az ózonterápia klinikai létjogosultságáról, 
mint kiegészítő kezelésről a MRONJ standard terápiája 
mellett [27]. Szintén pozitív hatással volt a MRONJ le-
folyására a kiegészítő hyperbaricus oxigénkezelés [28]. 
Akárcsak az LLLT-nél, itt is a kezelési módszer által in-
dukált biostimulatív hatásokat igyekeznek kihasználni 
(proliferáció, sebgyógyulás, fájdalomcsillapítás) a terápia 
során. Az amerikai társaság által kiadott szakmai ajánlás 
azonban nem támogatja ezt a kiegészítő kezelést, mivel a 
Freiberger és mtsai által közölt tanulmányban kevés esetet 
vizsgáltak, így azokból nem vonható le statisztikai kü-
lönbség.
Növekedési faktorok alkalmazása
Felmerült növekedési faktorok terápiás alkalmazhatósága 
is. Mozzati és mtsai kutatásuk során 32 MRONJ-beteg 
esetében a sebészileg kezelt területre növekedési fakto-
rokban gazdag plazmát juttattak, majd ez után zárták a 
1. ábra A jobb oldali mandibula necrosisának radiológiai képe
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nyálkahártyát. Mind a 32 esetben sikeres volt a beavatko-
zás, 48–50 hónapos utánkövetés során recidíva nem iga-
zolódott [29].
Sebészi lézerek alkalmazása
A nagy energiájú sebészi lézerek szövetek vágására, így 
például a necroticus csont vaporisatiójára is alkalmasak. 
A minimálisan invazív technika alkalmazásával nemcsak a 
műtéti precizitás fokozható, hanem a csontban kialakult 
mikroperforációk stimulusként hatnak az angiogenesis-
re, emellett a technika baktericid hatású, javítva ezzel is a 
posztoperatív felépülést. Összehasonlítva a hagyomá-
nyos sebészi kezeléssel, sokkal jobb eredmények érhetők 
el ezt a technikát alkalmazva [17].
Számos alap- és klinikai kutatás irányul újabb kezelési 
modalitások kidolgozására, azonban magas evidenciájú 
tudás jelenleg nem áll rendelkezésre, további vizsgálatok 
szükségesek, amelyet az amerikai ajánlás is hangsúlyoz 
[4]. Mindezek alapján kiemelkedő jelentőséget kapnak 
azok az eljárások, amelyek az állcsontnecrosis megelőzé-
sét és korai diagnózisát célozzák meg.
Hagyományos eljárások az állcsontnecrosis 
megelőzése és korai diagnózisa céljából
Kockázatbecslés a terápia megkezdése előtt
Közismert tény, hogy a spontán kialakuló osteonecrosis 
gyakorisága csekély, az invazív fogászati beavatkozások 
azonban jelentősen fokozzák a kialakulás rizikóját [30]. A 
korábban ismertetett egyéb rizikófaktorok (terápia mód-
ja, társbetegségek, életkor stb.) mindezt befolyásolhatják, 
éppen ezért kiemelkedően fontos a terápia megkezdése 
előtt a fogászati státus ellenőrzése és optimalizálása, a be-
tegek szoros utánkövetése [4], amellyel nagymértékben 
csökkenthető az osteonecrosis kialakulási esélye. Ugyan-
akkor a kezelést elrendelő orvosnak is fel kellene hívnia 
betege figyelmét az esetleges komplikációkra és az esetle-
ges korai tünetek felismerésének fontosságára. 
Kockázatbecslés fogászati beavatkozások 
megkezdése előtt
A kellően átfogó anamnézis segíthet az osteonecrosis 
megelőzésében. Invazív fogászati beavatkozások előtt 
tanácsos magára a gyógyszerhasználatra, akár a csontrit-
kulásra is rákérdezni, nemcsak az egyéb, fogászati be-
avatkozás kapcsán komplikációkat okozó gyógyszerekre. 
A tervezett fogászati beavatkozás ugyanis módosítható, 
biztonságosabbá tehető. A BIS-kezelés felfüggesztése – 
„drug holiday” – kapcsán ellentmondásosak a vélemé-
nyek, de általánosan elfogadott nézet, hogy egy 2 hóna-
pos gyógyszermentes időszak az invazív fogászati 
beavatkozás előtt csökkentheti a szövődmények kialaku-
lását BIS-kezelt betegekben [31]. Természetesen ez csak 
tervezett fogászati beavatkozások esetén az alapbeteg-
ség, az onkológiai és/vagy reumatológiai terápia indivi-
duális mérlegelése alapján jön szóba.
Az amerikai, a német és a hazai maxillofacialis társasá-
gok szakmai ajánlása alapján a BIS-kezelt betegeknél 
dentoalveolaris és invazív fogászati beavatkozások során 
javasolt a profilaktikus antibiotikumkezelés. Elsőként pe-
nicillinszármazékok választandók (amoxicillin 3×750 
mg/nap vagy amoxicillin+klavulánsav 3×625 mg/nap 
vagy 2×1 g/nap), allergia esetén quinolonszármazékok, 
macrolidok és lincosamidok (clarithromycin 2×250 mg/
nap, erythromycin, clindamycin 4×300-600 mg/nap), 
metronidazol és doxycyclin jöhetnek még számításba. Az 
antibiotikum adása a beavatkozást megelőzően 1-2 nap-
pal, illetve a primer sebgyógyulásig ajánlott (nagyjából 
10 napig), de egyéb indikáció esetén hosszabb ideig is 
szükséges lehet. A betegség korai stádiumában szintén 
javulást eredményezhet az antibiotikumkezelés [4, 32, 
33].
2. ábra Kiterjedt, kétoldali maxillanecrosis klinikai képe
3. ábra Jobb oldali mandibulanecrosis reszekcióját követő lemezes re-
konstrukció intraoperatív képe
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Laboratóriumi vizsgálómódszerek  
az állcsontnecrosis korai diagnózisa céljából
A MRONJ esetében egy lokalizált elváltozásról van szó, 
így a szisztémás paraméterekben nem vagy alig mutatha-
tó ki markáns eltérés [4]. Ezért nélkülözhetetlen lenne 
olyan diagnosztikai eljárások kidolgozása, amelyek révén 
a prediszponált populáció kiszűrhető még a kezelés meg-
kezdése előtt, vagy az elváltozás hatékonyan kimutatható 
a korai stádiumban a veszélyeztetett populációban.
Plazma- és szérumminták vizsgálata
A csontokban is megtalálható, főként kollagén I lebom-
lása során (csontreszorpció) terminális telopeptidek sza-
badulnak fel, majd a keringésbe kerülnek és további deg-
radáción már nem esnek át. Ezek aminosav-szekvenciái 
az I. típusú kollagénre erősen specifikusak. Így exkréció-
ja egyenesen arányos a csontreszorpció mértékével [34], 
valamint vizeletből és vérből (szérum) egyaránt megha-
tározhatók. A C-terminális (karboxiterminális) telopep-
tid (CTX), valamint az N-terminális (aminoterminális) 
telopeptid meghatározása a csontreszorpciót leginkább 
reprezentáló biokémiai markerek, amelyek az osteoporo-
siskezelés hatékonyságának követésére is alkalmasak [34, 
35]. Számos kutatás vizsgálta a CTX-értékek és MRONJ 
közötti korrelációt. Egyes kutatási eredmények alapján a 
CTX szintje, akár szérumból, akár vizeletből mérve, szo-
ros összefüggést mutatott az ostenecrosis kialakulási esé-
lyével, illetve a patológiás elváltozás fennállásával [36, 
37]. Az eljárás hátránya, hogy számos tényező befolyá-
solhatja a mérési eredményeket, ilyen a nem, az étkezési 
szokások és a gyomor teltségi állapota, az életkor, az év-
szak, a hormonszintek vagy akár a vesefunkció [34, 38]. 
Vescovi és mtsai szerint nem ad megbízható eredményt a 
vizsgálat daganatos megbetegedés vagy rheumatoid ar-
thritis kezelését (methotrexat, prednison, raloxafen) kö-
vetően [17], illetve teljesen normálértékek is detektálha-
tók MRONJ fennállása esetén, ami megkérdőjelezi a 
betegség és a szérum-CTX-szint közötti összefüggést 
[39]. 
In vitro és in vivo tanulmányok alátámasztották egyes 
intravénásan adagolt BIS-készítmények angiogenesist 
gátló hatását [40, 41], és ennek a jelenségnek szintén 
szerepe lehet a kórkép patogenezisében. Ezt támasztják 
alá azok a közlemények is, amelyekben leírják, hogy bár 
a malignus tumorok kezelésénél kifejezetten előnyösnek 
bizonyult az angiogenesist gátló terápia, mégis a BIS és 
angiogenesist gátló együttes adása mellett a MRONJ in-
cidenciája jelentősen emelkedhet. Egyes retrospektív ta-
nulmányok az osteonecrosisráta megduplázódását írják 
le [42, 43]. Mivel a MRONJ kialakulása során szignifi-
káns érendothelium-eredetű növekedési faktor (vascular 
endothelial growth factor – VEGF) szint csökkenést 
mértek a szérumban, felmerül a VEGF-szint mérésének 
szűrésben való felhasználhatósága. Habár felmerült, 
hogy a VEGF, mint angiogén marker, jó kórjelzője lehet 
a MRONJ kialakulásának [40], irodalmi adatok – hason-
lóan a CTX-méréshez – jelentős eltéréseket mutatnak a 
mérés szenzitivitásával kapcsolatban [44].
Biomarkerek meghatározása nyálból 
Az egyre fejlődő biokémiai módszereknek és technikai 
megoldásoknak köszönhetően ma már lehetőség van 
sokfajta biomarker mérésére nyálból, amelyek alkalmasak 
a csontfolyamatok megítélésére. A BIS-ok ismert osteoc-
last-aktivitást gátló hatásuknak [3] köszönhetően az os-
teoblast-tevékenység kerülhet túlsúlyba. A csontspecifi-
kus alkalikus foszfatáz, az osteonectin és osteocalcin az 
osteoblast-aktivitás jellemző paraméterei, amelyek a szé-
rumban mért értékkel jól korrelálnak [45]. Ez a paramé-
ter MRONJ-ban szenvedő betegek esetében szignifikán-
san alacsonyabb értéket mutatott a BIS-sel kezelt, de 
necrosissal nem rendelkező betegek értékeihez képest 
[39]. A foghúzáson átesett, BIS-terápiában részesülő be-
tegek szűrése az említett biomarkerek szintjének megha-
tározásával nem számítanak rutinvizsgálatoknak, kizáró-
lag kutatások tárgyát képezik. 
A BIS-ek gyulladást keltő hatásai [46, 47] és a folya-
mat krónikus volta miatt a gyulladásos mediátorok vizs-
gálata is szóba jöhet. Ng és mtsai az IL-1b, TNF-α, IL-6 
szintjét ellenőrizték nyálból, következtetésük alapján 
ezek szintje jól monitorozza, sőt előre jelzi a periodonta-
lis betegségekre való érzékenységet. A módszer limitáci-
ója, hogy a nyálban ezek a mediátorok gyorsan lebomla-
nak, megnehezítve ezzel az abszolút koncentráció 
pontos meghatározását [45]. Más tanulmányokban IL-
1α-, IL-4-, IL-6-, IL-8-, EGF-, MCP-1-, TNF-α-szintek 
kerültek detektálásra, amelyekből azt a következtetést 
vonták le, hogy a gyulladásos paraméterek szintje és ezek 
változásai eleve eltérhetnek daganatos betegekben a száj-
üregi folyamatok során [48, 49]. Az egyes citokinszin-
tekben történő változások a MRONJ patogenezise kap-
csán még nem teljesen tisztázottak, mivel prospektív 
vizsgálatok még hiányoznak ebben a tekintetben.
Az oxidoreduktív stresszt jellemző anyagcseretermé-
kek (redukált glutation, malondialdehid, oxidált glutati-
on és 8-oxo-7,8-dihidro-2-deoxiguanozin) mérése szin-
tén jó megközelítése lehet a szájüregi gyulladásos 
folyamatok detektálásának. Bagan és mtsai a fent említett 
paraméterek vonatkozásában szignifikáns emelkedést 
mértek BIS-kezelt és osteonecrosisos betegek nyálmintá-
iban az egészséges páciensek értékeihez képest [50], 
ezek specificitása/szenzitivitása azonban szintén kérdé-
ses.
Következtetés
A gyógyszer indukálta állcsontnecrosisok prevenciójának 
és terápiájának egyik legnagyobb hátránya, hogy mind a 
mai napig nem rendelkezünk magas szintű evidenciaala-
pú tudással. Éppen ezért kiemelkedő jelentősége van az 
adatgyűjtés mellett a magas evidenciájú klinikai kutatá-
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sok folytatásának. Ehhez elengedhetetlen az interdisz-
ciplináris együttműködés, amely egyben az eredményes 
kezeléseknek is az alapja. A jelenleg érvényben lévő nem-
zetközi szakmai ajánlás maximálisan a konzervatív terá-
pia mellett foglal állást, késleltetve a sebészeti intervenci-
ót, amely nem minden esetben hozza meg az elvárt 
sikert. A kezelés terén beigazolódni látszik a minimálisan 
invazív sebészi technika szükségessége, amely sok eset-
ben – a betegek előrehaladott alapbetegségét is figyelem-
be véve – helyi érzéstelenítésben is elvégezhető, ezáltal 
idősebb és immunszuppresszív terápiában részesült bete-
geknél is alkalmazható, illetve a sebészi defektus méreté-
nek minimalizálásával csökken a sebgyógyulási zavar ve-
szélye is.
Anyagi támogatás: TÁMOP-4.2.2.A-11/1/KONV-
2012-0035, TÁMOP 4.2.4.A/2-11-1-2012-0001, 
OTKA-109388.
Szerzői munkamegosztás: J. Á., V. T.: A kézirat megírása, 
szakirodalmi adatgyűjtés. Sz. A., P. J.: Szakmai lektorá-
lás. A cikk végleges változatát valamennyi szerző elolvas-
ta és jóváhagyta.
Érdekeltségek: A szerzőknek nincsenek érdekeltségeik.
Irodalom
[1] Kerschan-Schindl, K., Patsch, J., Kudlacek, S., et al.: Measuring 
quality of life with the German Osteoporosis Quality of Life 
Questionnaire in women with osteoporosis. Wien. Klin. Wochen-
schr., 2012, 124(15–16), 532–537.
[2] Wilson, S., Sharp, C. A., Davie, M. W.: Health-related quality of 
life in patients with osteoporosis in the absence of vertebral frac-
ture: a systematic review. Osteoporos. Int., 2012, 23(12), 2749–
2768.
[3] Brozoski, M. A., Traina, A. A., Deboni, M. C., et al.: Bisphospho-
nate-related osteonecrosis of the jaw. Rev. Bras. Reumatol., 
2012, 52(2), 265–270.
[4] Ruggiero, S. L., Dodson, T. B., Fantasia, J., et al.: American As-
sociation of Oral and Maxillofacial Surgeons position paper on 
medication-related osteonecrosis of the jaw –2014 update. J. 
Oral. Maxillofac. Surg., 2014, 72(10), 1938–1956.
[5] Aghaloo, T. L., Felsenfeld, A. L., Tetradis, S.: Osteonecrosis of the 
jaw in a patient on Denosumab. J. Oral. Maxillofac. Surg., 2010, 
68(5), 959–963.
[6] Serra, E., Paolantonio, M., Spoto, G., et al.: Bevacizumab-related 
osteonecrosis of the jaw. Int. J. Immunopathol. Pharmacol., 
2009, 22(4), 1121–1123.
[7] Otto, S., Schreyer, C., Hafner, S., et al.: Bisphosphonate-related 
osteonecrosis of the jaws – characteristics, risk factors, clinical 
features, localization and impact on oncological treatment. J. 
Craniomaxillofac. Surg., 2012, 40(4), 303–309.
[8] Marx, R. E.: Reconstruction of defects caused by bisphospho-
nate-induced osteonecrosis of the jaws. J. Oral. Maxillofac. 
Surg., 2009, 67(5), Suppl. 107–119.
[9] Vescovi, P., Merigo, E., Meleti, M., et al.: Surgical approach and 
laser applications in BRONJ osteoporotic and cancer patients. J. 
Osteoporos., 2012, 2012, 585434.
[10] Mawardi, H., Giro, G., Kajiya, M., et al.: A role of oral bacteria 
in bisphosphonate-induced osteonecrosis of the jaw. J. Dent. 
Res., 2011, 90(11), 1339–1345.
[11] Reid, I. R., Bolland, M. J., Grey, A. B.: Is bisphosphonate-associ-
ated osteonecrosis of the jaw caused by soft tissue toxicity? Bone, 
2007, 41(3), 318–320.
[12] Wood, J., Bonjean, K., Ruetz, S., et al.: Novel antiangiogenic ef-
fects of the bisphosphonate compound zoledronic acid. J. Phar-
macol. Exp. Ther., 2002, 302(3), 1055–1061.
[13] Schuiling, K. D., Robinia, K., Nye, R.: Osteoporosis update. J. 
Midwifery Womens Health, 2011, 56(6), 615–627.
[14] Tolia, M., Zygogianni, A., Kouvaris, J. R., et al.: The key role of 
bisphosphonates in the supportive care of cancer patients. Anti-
cancer Res., 2014, 34(1), 23–37.
[15] Lee, J. J., Cheng, S. J., Jeng, J. H., et al.: Successful treatment of 
advanced bisphosphonate-related osteonecrosis of the mandible 
with adjunctive teriparatide therapy. Head Neck, 2011, 33(9), 
1366–1371.
[16] Orwoll, E. S., Scheele, W H., Paul, S., et al.: The effect of teripara-
tide [human parathyroid hormone (1–34)] therapy on bone den-
sity in men with osteoporosis. J. Bone Miner. Res., 2003, 18(1), 
9–17.
[17] Vescovi, P., Merigo, E., Meleti, M., et al.: Conservative surgical 
management of stage I bisphosphonate-related osteonecrosis of 
the jaw. Int. J. Dent., 2014, 2014, 107690.
[18] Andrews, E. B., Gilsenan, A. W., Midkiff, K., et al.: The US post-
marketing surveillance study of adult osteosarcoma and teripara-
tide: study design and findings from the first 7 years. J. Bone 
Miner. Res., 2012, 27(12), 2429–2437.
[19] Epstein, M. S., Wicknick, F. W., Epstein, J. B., et al.: Management 
of bisphosphonate-associated osteonecrosis: pentoxifylline and 
tocopherol in addition to antimicrobial therapy. An initial case 
series. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 
2010, 110(5), 593–596.
[20] Delanian, S., Porcher, R., Rudant, J., et al.: Kinetics of response 
to long-term treatment combining pentoxifylline and tocopherol 
in patients with superficial radiation-induced fibrosis. J. Clin. 
Oncol., 2005, 23(34), 8570–8579.
[21] Tousoulis, D., Antoniades, C., Vassiliadou, C., et al.: Effects of 
combined administration of low dose atorvastatin and vitamin E 
on inflammatory markers and endothelial function in patients 
with heart failure. Eur. J. Heart Fail., 2005, 7(7), 1126–1132.
[22] Albertini, R., Villaverde, A. B., Aimbire, F., et al.: Anti-inflamma-
tory effects of low-level laser therapy (LLLT) with two different 
red wavelengths (660 nm and 684 nm) in carrageenan-induced 
rat paw edema. J. Photochem. Photobiol. B, 2007, 89(1), 50–
55.
[23] Salate, A. C., Barbosa, G., Gaspar, P., et al.: Effect of In-Ga-Al-P 
diode laser irradiation on angiogenesis in partial ruptures of 
Achilles tendon in rats. Photomed. Laser Surg., 2005, 23(5), 
470–475.
[24] Nicola, R. A., Jorgetti, V., Rigau, J., et al.: Effect of low-power 
GaAlAs laser (660 nm) on bone structure and cell activity: an 
experimental animal study. Lasers Med. Sci., 2003, 18(2), 89–
94.
[25] Frozanfar, A., Ramezani, M., Rahpeyma, A., et al.: The effects of 
low level laser therapy on the expression of collagen type I gene 
and proliferation of human gingival fibroblasts (Hgf3-Pi 53): in 
vitro study. Iran J. Basic Med. Sci. 2013, 16(10), 1071–1074.
[26] Scoletta, M., Arduino, P. G., Reggio, L., et al.: Effect of low-level 
laser irradiation on bisphosphonate-induced osteonecrosis of the 
jaws: preliminary results of a prospective study. Photomed. Laser 
Surg., 2010, 28(2), 179–184.
[27] Agrillo, A., Filiaci, F., Ramieri, V., et al.: Bisphosphonate-related 
osteonecrosis of the jaw (BRONJ): 5 year experience in the treat-
ment of 131 cases with ozone therapy. Eur. Rev. Med. Pharma-
col. Sci., 2012, 16(12), 1741–1747.
[28] Freiberger, J. J., Padilla-Burgos, R., McGraw, T., et al.: What is 
the role of hyperbaric oxygen in the management of bisphospho-
nate-related osteonecrosis of the jaw: a randomized controlled 
2014  ■  155. évfolyam, 49. szám ORVOSI HETILAP1966
ÖSSZEFOGLALÓ KÖZLEMÉNY
trial of hyperbaric oxygen as an adjunct to surgery and antibiot-
ics. J. Oral Maxillofac. Surg., 2012, 70(7), 1573–1583.
[29] Mozzati, M., Gallesio, G., Arata, V., et al.: Platelet-rich therapies 
in the treatment of intravenous bisphosphonate-related osteone-
crosis of the jaw: a report of 32 cases. Oral Oncol., 2012, 48(5), 
469–474.
[30] Farrugia, M. C., Summerlin, D. J., Krowiak, E., et al.: Osteone-
crosis of the mandible or maxilla associated with the use of new 
generation bisphosphonates. Laryngoscope, 2006, 116(1), 115–
120.
[31] Damm, D. D., Jones, D. M.: Bisphosphonate-related osteonecro-
sis of the jaws: a potential alternative to drug holidays. Gen. 
Dent., 2013, 61(5), 33–38.
[32] Hungarian Society of Oral and Maxillofacial Surgeons, Hungar-
ian Society of Osteoporosis and Osteoarthrosis, Hungarian Society 
of Oncologists, Hungarian Rheumatology Association, Hungarian 
Society of Orthopedic: Bisphosphonate-induced jaw osteonecrosis 
prevention and treatment. [Magyar Arc-, Állcsont- és Szájse-
bészeti Társaság, Magyar Osteoporosis és Osteoarthrologiai Tár-
saság, Magyar Onkológusok Társasága, Magyar Reumatológu-
sok Egyesülete, Magyar Ortopéd Társaság: A biszfoszfonátok 
által indukált állcsont-osteonecrosisok megelőzése és kezelése.] 
Orv. Hetil., 2010, 151(4), 148–149. [Hungarian]
[33] Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde: 
http://www.dgzmk.de/zahnaerzte/wissenschaft-forschung/
leitlinien.html
[34] Chubb, S. A.: Measurement of C-terminal telopeptide of type I 
collagen (CTX) in serum. Clin. Biochem., 2012, 45(12), 928–
935.
[35] Hodsman, A. B., Fraher, L. J., Ostbye, T., et al.: An evaluation of 
several biochemical markers for bone formation and resorption 
in a protocol utilizing cyclical parathyroid hormone and calci-
tonin therapy for osteoporosis. J. Clin. Invest., 1993, 91(3), 
1138–1148.
[36] Baim, S., Miller, P. D.: Assessing the clinical utility of serum CTX 
in postmenopausal osteoporosis and its use in predicting risk of 
osteonecrosis of the jaw. J. Bone Miner. Res., 2009, 24(4), 561–
574.
[37] Pellegrini, G. G., Gonzales Chaves, M. M., Fajardo, M. A., et al.: 
Salivary bone turnover markers in healthy pre- and postmeno-
pausal women: daily and seasonal rhythm. Clin. Oral Investig., 
2012, 16(2), 651–657.
[38] Borromeo, G. L., Tsao, C. E., Darby, I. B., et al.: A review of the 
clinical implications of bisphosphonates in dentistry. Aust. Dent. 
J., 2011, 56(1), 2–9.
[39] Lazarovici, T. S., Mesilaty-Gross, S., Vered, I., et al.: Serologic 
bone markers for predicting development of osteonecrosis of the 
jaw in patients receiving bisphosphonates. J. Oral Maxillofac. 
Surg., 2010, 68(9), 2241–2247.
[40] Vincenzi, B., Napolitano, A., Zoccoli, A., et al.: Serum VEGF lev-
els as predictive marker of bisphosphonate-related osteonecrosis 
of the jaw. J. Hematol. Oncol., 2012, 5, 56.
[41] Ziebart, T., Pabst, A., Klein, M. O., et al.: Bisphosphonates: re-
strictions for vasculogenesis and angiogenesis: inhibition of cell 
function of endothelial progenitor cells and mature endothelial 
cells in vitro. Clin. Oral Investig., 2011, 15(1), 105–111.
[42] Aragon-Ching, J. B., Ning, Y. M., Chen, C. C., et al.: Higher in-
cidence of Osteonecrosis of the Jaw (ONJ) in patients with met-
astatic castration resistant prostate cancer treated with anti-angi-
ogenic agents. Cancer Invest., 2009, 27(2), 221–226.
[43] Pakosch, D., Papadimas, D., Munding, J., et al.: Osteonecrosis of 
the mandible due to anti-angiogenic agent, bevacizumab. Oral 
Maxillofac. Surg., 2013, 17(4), 303–306.
[44] Brozovic, S., Vucicevic-Boras, V., Mravak-Stipetic, M., et al.: Sali-
vary levels of vascular endothelial growth factor (VEGF) in re-
current aphthous ulceration. J. Oral Pathol. Med., 2002, 31(2), 
106–108.
[45] Ng, P. Y., Donley, M., Hausmann, E., et al.: Candidate salivary 
biomarkers associated with alveolar bone loss: cross-sectional and 
in vitro studies. FEMS Immunol. Med. Microbiol., 2007, 49(2), 
252–260.
[46] Senel, F. C., Kadioglu Duman, M., Muci, E., et al.: Jaw bone 
changes in rats after treatment with zoledronate and pa-
midronate. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. En-
dod., 2010, 109(3), 385–391.
[47] Norton, J. T., Hayashi, T., Crain, B., et al.: Cutting edge: nitro-
gen bisphosphonate-induced inflammation is dependent upon 
mast cells and IL-1. J. Immunol., 2012, 188(7), 2977–2980.
[48] Citrin, D. E., Hitchcock, Y. J., Chung, E. J., et al.: Determination 
of cytokine protein levels in oral secretions in patients undergo-
ing radiotherapy for head and neck malignancies. Radiat. Oncol., 
2012, 7, 64.
[49] Korostoff, A., Reder, L., Masood, R., et al.: The role of salivary 
cytokine biomarkers in tongue cancer invasion and mortality. 
Oral Oncol., 2011, 47(4), 282–287.
[50] Bagan, J., Sáez, G. T., Tormos, M. C., et al.: Oxidative stress in 
bisphosphonate-related osteonecrosis of the jaws. J. Oral Pathol. 
Med., 2014, 43(5), 371–377.
 (Janovszky Ágnes dr.,
Szeged, Kálvária sgt. 57., 6725
e-mail: agnes.janovszky@gmail.com)
  
 
 
 
 
 
 
 
 
 
 
 
 
III. 
 
 
ORIGINAL ARTICLE
Periosteal microcirculatory reactions in a zoledronate-induced
osteonecrosis model of the jaw in rats
Ágnes Janovszky & Andrea Szabó & Renáta Varga & Dénes Garab & Mihály Boros &
Csilla Mester & Nikolett Beretka & Tamás Zombori & Hans-Peter Wiesmann &
Ricardo Bernhardt & Imre Ocsovszki & Péter Balázs & József Piffkó
Received: 6 August 2014 /Accepted: 22 October 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract
Objectives Nitrogen-containing bisphosphonates induce
osteonecrosis mostly in the jaw and less frequently in other
bones. Because of the crucial role of periosteal perfusion in
bone repair, we investigated zoledronate-induced microcircu-
latory reactions in the mandibular periosteum in comparison
with those in the tibia in a clinically relevant model of
bisphosphonate-induced medication-related osteonecrosis of
the jaw (MRONJ).
Materials and methods Sprague–Dawley rats were treated
with zoledronate (ZOL; 80 i.v. μg/kg/week over 8 weeks) or
saline vehicle. The first two right mandibular molar teeth were
extracted after 3 weeks. Various systemic and local
(periosteal) microcirculatory inflammatory parameters were
examined by intravital videomicroscopy after 9 weeks.
Results Gingival healing disorders (∼100 %) and MRONJ
developed in 70 % of ZOL-treated cases but not after saline
(shown by micro-CT). ZOL induced significantly higher de-
grees of periosteal leukocyte rolling and adhesion in the
mandibular postcapillary venules (at both extraction and intact
sites) than at the tibia. Leukocyte NADPH-oxidase activity
was reduced; leukocyte CD11b and plasma TNF-alpha levels
were unchanged.
Conclusion Chronic ZOL treatment causes a distinct micro-
circulatory inflammatory reaction in the mandibular perioste-
um but not in the tibia. The local reaction in the absence of
augmented systemic leukocyte inflammatory activity suggests
that topically different, endothelium-specific changes may
play a critical role in the pathogenesis of MRONJ.
Clinical relevance This model permits for the first time to
explore the microvascular processes in the mandibular peri-
osteum after chronic ZOL treatment. This approach may
contribute to a better understanding of the pathomechanism
and the development of strategies to counteract
bisphosphonate-induced side effects.
Keywords Mandibular periosteum . Intravital fluorescence
videomicroscopy . Leukocytes . Inflammation .
Bisphosphonate . Osteonecrosis
Introduction
Bisphosphonates (BISs) are widely used for the treatment of
osteoporosis and tumors with bone metastasis. The therapeu-
tic effect is linked to the inhibition of osteoclast activity, which
alters the bone metabolism by inhibiting bone resorption and
reducing the bone turnover [1]. Although BIS treatment un-
doubtedly improves the quality of life of the patients,
osteonecrosis is a serious adverse effect in a number of cases
[2]. BIS-related osteonecrosis of the jaw (recently termed as
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medication-related osteonecrosis of the jaw; MRONJ) occurs
mainly after invasive dental procedures, e.g., tooth extraction
[3], with an increased incidence particularly after the use of
third-generation BISs (e.g., zoledronate, ZOL) [1]. MRONJ
most probably has a multifactorial etiology and is influenced
by numerous factors, including the administration route and
dose, the duration of the therapy, the indication of BIS admin-
istration (osteoporosis or oncological reason), co-morbidities,
the concomitant use of other drugs (corticosteroids or chemo-
therapeutics), genetic factors, age, and poor oral hygiene [1,
3]. Local contamination and infection evoked by invasive
dental procedures in the presence of BIS treatment have also
been emphasized in the development of MRONJ [4].
Osteonecrosis, however, can develop several years later,
which may be explained by the long half-lives of these med-
ications [1] and not by the acute infectious induction. More-
over, BIS treatment has been shown to cause sterile inflam-
matory reactions such as aseptic peritonitis [5, 6] and an
enhancement of leukocyte–endothelial cell interactions in
the knee joint [7]. These effects may be linked to an upregu-
lation of pro-inflammatory cytokines such as IL-1 and TNF-
alpha [6–8] in response to BIS administration. The effects of
BISs also exhibit spatial differences, because certain inflam-
matory reactions are confined to the mandible and not present
in the femur [9]. Nevertheless, the exact pathomechanism of
MRONJ has not yet been clarified, and the possibilities of its
prevention or the use of curative modalities are also limited.
The periosteal perfusion significantly influences bone
healing and determines the prognosis of adjacent soft tissue
traumas as well [10]. Little, however, is known about the
microcirculatory effects of BIS and especially the microcircu-
lation of the mandible. Likewise, to date, no data are available
on the periosteal changes after invasive dental procedures
involving BIS treatment. In this study, we hypothesized that
a disturbed mandibular microcirculation may play a role in the
pathogenesis of MRONJ. With this background, we designed
an animal model ofMRONJ with the possibility of visualizing
the mandibular microcirculation by means of an intravital
videomicroscopy (IVM) technique. Our aims were to observe
and compare the mandibular and tibial periosteal microcircu-
latory reactions in rats subjected to chronic ZOL treatment
with or without tooth extraction.
Materials and methods
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless indicated otherwise. The study was per-
formed in accordance with the Guidelines laid down by the
National Institute of Health (NIH) in the USA regarding the
care and use of animals for experimental procedures and with
the 2010/63/EU Directive and was approved by the Animal
Welfare Committee of the University of Szeged (V/1639/
2013).
Experimental protocol
Twenty male Sprague–Dawley rats (average initial body
weight of 200±10 g) were randomly allocated to saline
vehicle-treated control (n=10) or intravenously (i.v.) ZOL-
treated (n=10, ZOL) groups. ZOL (zoledronic acid, Zometa,
Novartis Europharm, Budapest, Hungary) was administered
through the tail vein in a dose of 80 μg/kg once a week for
8 weeks. At the end of the 3rd week of the protocol, the first
and second molar teeth on the right side were extracted from
the mandible under ketamine and xylazine (i.p. 25 and
75 mg/kg, respectively) anesthesia. The teeth were luxated
with an 18G needle, and the extraction was performed with
extraction forceps. The roots were also removed with a dental
drill under a Zeiss operating microscope (×6 magnification;
Carl Zeiss GmbH, Jena, Germany). By thesemeans, the defect
was equal in size and severity in all rats. For pain relief,
intramuscular ketoprofen (Ketodex Forte; Berlin-Chemie
AG, Berlin, Germany; 5 mg/kg) and oral metamizole sodium
(Algopyrin; Sanofi-Aventis, Budapest, Hungary; 75 mg/kg)
were administered for 3 days. Mucosal healing processes were
monitored continuously throughout the experimental period.
Microcirculatory variables were examined on the 9th week
of the protocol. The animals were anesthetized intraperitone-
ally with an initial dose of sodium pentobarbital (45 mg/kg)
and placed in a supine position on a heating pad to maintain
the body temperature at 36–37 °C. Following cannulation of
the trachea, the penile vein was cannulated for the adminis-
tration of fluid and drugs (supplementary dose of sodium
pentobarbital; 5 mg/kg). This was followed by cannulation
of the femoral artery on the right side, and blood was drawn
for the white blood cell count and determination of the differ-
ent markers of leukocyte function/activation and inflamma-
tion (see later).
The mandibular periosteum was exposed for fluorescence
IVM on both sides, in the vicinity of the earlier extraction area
and on the contralateral side, between the anterior part of the
deep masseter and the anterior superficial masseter muscles,
as described elsewhere [11]. Briefly, an incision was made
parallel to the incisor tooth in the facial skin and the underly-
ing subcutaneous tissue, and the loose connective tissue be-
tween the fascia of the deep masseter and the anterior super-
ficial masseter muscles was carefully cut, using a microsurgi-
cal approach under an operating microscope (×6 magnifica-
tion; Carl Zeiss GmbH, Jena, Germany). By this means, the
periosteal membrane covering the corpus of the mandible at
the anterior margin of the molar region was reached, laterally/
distally to the incisor tooth. To aid better exposure for the
microscope objective, retraction was achieved by placing
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stitches with 7.0 monofilament polypropylene microsurgical
thread into the surrounding masseter muscles. For comparison
of the characteristics of the mandibular microcirculation with
those of the tibial periosteum, the medial/anterior surface of
the left tibia was exposed by complete transection of the
anterior gracilis muscle with microscissors and careful
atraumatic microsurgical removal of the connective tissue
covering the tibial periosteum [12]. After the IVM recordings
of the microcirculation, the animals were over-anesthetized
with a single overdose of pentobarbital, and the mandibles
were removed and placed into 10 % buffered formalin
solution for subsequent detection of osteonecrosis of the
mandible through micro-CT and histological analyses.
Fluorescence IVM
The exposed periosteal surfaces of the mandible (on
both the extracted and intact sides) and of the tibia
were consecutively examined by IVM. The exposed
surfaces were positioned horizontally on an adjustable
stage and superfused with 37 °C saline. The periosteal
microcirculation was visualized by IVM (penetration
depth: approx. 250 μm; Zeiss Axiotech Vario 100HD
microscope; 100-W HBO mercury lamp; Acroplan 20×/
0.5 N.A. W, Carl Zeiss GmbH, Jena, Germany). Fluo-
rescein isothiocyanate-labeled erythrocytes (0.2 ml i.v.)
were used to stain red blood cells and rhodamine-6G
(0.2 %, 0.1 ml i.v.) to stain leukocytes. Images from
four to five fields of the mandibular and the tibial
periosteum from each rat were recorded with a charge-
coupled device video camera (Teli CS8320Bi, Toshiba
Teli Corporation, Osaka, Japan) attached to an S-VHS
video recorder (Panasonic AG-MD 830; Matsushita
Electric Industrial Co., Tokyo, Japan) and a personal
computer.
Video analysis
Quantitative evaluation of the microcirculatory parameters
was performed off-line by the frame-to-frame analysis of the
videotaped images taken for IVM (IVM Software; Pictron
Ltd, Budapest, Hungary). Leukocyte–endothelial cell interac-
tions were analyzed in at least four postcapillary venules per
rat. Rolling leukocytes were defined as cells moving with a
velocity less than 40 % of that of the erythrocytes in the
centerline of the microvessel and passing through the ob-
served vessel segment within 30 s and are given as the number
of cells per second per vessel circumference. Adherent leuko-
cytes were defined as cells that did not move or detach from
the endothelial lining within an observation period of 30 s and
are given as the number of cells per square millimeter of
endothelial surface, calculated from the diameter and length
of the vessel segment. Red blood cell velocity (RBCV, μm/s)
was determined by frame-to-frame analysis of five to six
consecutive video-captured images taken after labeling of
the erythrocytes.
NADPH-oxidase activity of neutrophil leukocytes
The NADPH-oxidase activity of the isolated leukocytes
was determined by a modified chemiluminometric method
described by Bencsik et al. [13]. Blood was drawn from
the femoral artery into EDTA-containing tubes, and the
erythrocytes in 100 μl of whole blood were lyzed in a
hypotonic solution and centrifuged at 2000 g. The pellet
was resuspended and washed twice in a Dulbecco’s
phosphate-buffered saline solution. Twenty microliters of
resuspended pellet was incubated for 3 min at 37 °C in
Dulbecco’s solution containing lucigenin (1 mM), EGTA
(1 mM) and saccharose (140 mM). NADPH-oxidase ac-
tivity was determined via the NADPH-dependent increase
in luminescence elicited by adding 100 mM NADPH (in
20 μl), measured with an FB12 Single Tube Luminometer
(Berthold Detection Systems GmbH, Bad Wildbad, Ger-
many). Samples incubated in the presence of nitroblue
tetrazolium served as controls. The measurements were
performed in triplicates and were normalized for protein
content.
Whole blood free radical production
Ten microliters of blood dissolved in Hanks buffer was incu-
bated for 20 min at 37 °C in lucigenin (5 mM; dissolved in
Hanks buffer) or luminol (15 mM; dissolved in Hanks buffer)
solution in the presence or absence of zymozan (190 μM,
dissolved in Hanks buffer). Superoxide and hydrogen perox-
ide production were estimated via the zymozan-induced in-
crease in chemiluminescence (measured with the above
luminometer) and normalized for leukocyte counts in the
peripheral blood.
Expression of CD11b adhesion molecule on neutrophil
leukocytes
The surface expression of CD11b on the peripheral blood
granulocytes was determined by flow cytometric analysis as
detailed elsewhere [12], with a CyFlow ML (Partec GmbH,
Münster, Germany).
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Plasma TNF-alpha content
Blood samples were centrifuged at 13.500 rpm for 5 min at
4 °C and then stored at 70 °C until assayed. Plasma TNF-alpha
concentrations were determined in duplicate by means of a
commercially available ELISA kit (R&D Systems, Minneap-
olis, MN, USA).
Evaluation of the gingival lesions
Healing of the gingiva at the end of the study period (6 weeks
after the tooth extraction) was determined on the basis of an
osteonecrosis staging system provided by the American As-
sociation of Oral and Maxillofacial Surgeons [3]; this was
adapted for rats (see Table 1). The examination was performed
under an operating microscope (×6 magnification; Carl Zeiss
GmbH, Jena, Germany) by an independent maxillofacial sur-
geon. The incidence and the severity of the gingival healing
disorder were evaluated simultaneously.
Mandibular osteonecrosis as determined by micro-CT
Mandibles fixed with formaldehyde were used for micro-CT
imaging (SCANCO vivaCT 75; Scanco Medical, Brüttisellen,
Switzerland); subsequent analysis was performed on 2D sec-
tions in the coronal view of the images, the section being
chosen that showed the highest degree of tissue defect at the
earlier extraction site. The mean density of the bone was
estimated via the calculated percentage of the radiolucent area
of the alveolar portion of the bone.
Mandibular osteonecrosis as determined by histology
The specimens were fixed in 6 % neutral buffered formalin for
10 days, then rinsed in phosphate-buffered saline and
decalcified in 5 % EDTA for 7 days. The decalcified speci-
mens were embedded in paraffin and cut into 20 semi-serial
sections with a microtome (Shandon Finesse 325; Thermo
Scientific, Waltham, MA, USA), and routine hematoxylin
and eosin (H&E) staining was performed. The sections were
examined under a light microscope at ×4–40 magnification
(Model CHT; Olympus, Hamburg, Germany). The incidence
of osteonecrosis of the jaw was determined on the basis of
characteristic signs of necrosis, such as missing nuclear stain-
ing, the development of sequester formation and inflammato-
ry infiltration.
Statistical analysis
The statistical analysis was performed with a statistical
software package (SigmaStat for Windows; Jandel Sci-
entific, Erkrath, Germany). For the analysis of microcir-
culatory parameters, changes in variables within and
between groups (with respect to location and treatment,
separately) were analyzed by the two-way ANOVA test,
followed by the Holm–Sidak test. Differences between
groups (other inflammatory parameters and scores) were
analyzed with the Student t test. Data are presented as
mean values and SEM in all Figures and Tables. P
values <0.05 were considered significant.
Results
Microcirculatory inflammatory reactions
IVM recordings of the microcirculation were performed in a
mandibular periosteal region just adjacent to the site of the
Table 1 Scoring of macroscopic signs of the bisphosphonate-related
healing processes after tooth extraction (adopted from the staging of
MRONJ by Ruggiero et al. [3])
Score Exposed bone Inflammation/infection Fistula formation
Score 0 − − −
Score 1 + − −
Score 2 + + −
Score 3 + + +
Fig. 1 Periosteal primary leukocyte–endothelial cell interactions
(rolling) in saline- and ZOL-treated animals in the postcapillary venules
of the mandible on the tooth extraction (Ex) and the contralateral (C) sides
and in the tibia. Data are presented as means±SEM. Asterisk indicates
P<0.01 vs. the corresponding saline-treated group. The pound sign
indicates P<0.05 vs. the tibia. Two-way ANOVA was followed by the
Holm–Sidak test
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earlier tooth extraction and also on the contralateral side. Data
were compared with those on the tibial periosteum.
In vivo microscopy revealed homogenous microvas-
cular perfusion in all of the periosteal tissues examined;
the RBCVs were similar in the mandibular and tibial
capillary beds (827.5±30.1 μm/s and 739.0±37.7 μm/s,
respectively). The data were similar on the two sides of
the mandible and were not influenced by chronic ZOL
treatment (data not shown).
However, the leukocyte rolling in the postcapillary
venules of the mandible in the ZOL-treated group was
significantly higher than in the saline-treated group both
at the site of tooth extraction and on the contralateral
side; the differences between the sites were not statisti-
cally significant (Fig. 1). Similar differences were ob-
served in the leukocyte adhesion values after ZOL,
which revealed a statistically significant enhancement
in the mandibular periosteum as compared with the
tibial periosteum (Fig. 2). ZOL evoked similar rolling
and adhesion values irrespectively of the presence of
MRONJ (data not shown). The tibial microcirculation
was characterized by higher leukocyte rolling but simi-
lar adhesion in comparison with the data obtained for
the mandible in the saline-treated animals; none of them
were influenced by ZOL at this location.
Free radical production of leukocytes
The NADPH-oxidase activity of the neutrophil leuko-
cytes harvested from ZOL-treated animals was signifi-
cantly lower than that from the control animals
(Fig. 3a). The free radical-derived chemiluminescence
of the whole blood (as determined by the superoxide
and hydroxyl radical-dependent chemiluminescence mea-
surements) indicated no differences between the two
experimental groups (Fig. 3b).
Other inflammatory parameters
To exclude the possibility of increased leukocyte counts be-
hind the increased PMN rolling and adhesion after ZOL
treatment, the number of PMNs was determined with the
conventional Türk solution staining method and using a he-
mocytometer. As expected, the number of PMN leukocytes
was not higher (but rather even lower) in the rats chronically
treated with ZOL (Table 2).
As evidenced by the mean fluorescence values of the
adhesion molecule CD11b within the leukocyte population
(as measured by flow cytometry), no significant differences
were detected between the saline- and ZOL-treated animals
(Table 2).
There were no differences between the saline- and ZOL-
treated experimental groups with respect to the plasma TNF-
alpha levels either (n=6 and n=5, respectively) (Table 2).
Fig. 2 Periosteal secondary leukocyte–endothelial cell interactions
(sticking) in the postcapillary venules of the mandible on the tooth
extraction (Ex) and the contralateral (C) sides and in the tibia in saline-
and ZOL-treated animals. Data are presented as means±SEM. Asterisk
indicates P<0.01 vs. the corresponding saline-treated group. The pound
sign indicates P<0.01 vs. the tibia. Two-way ANOVAwas followed by
the Holm–Sidak test
Fig. 3 The effects of chronic
ZOL treatment on leukocyte
NADPH-oxidase activity (a) and
whole blood free radical
production (b) (the latter shown
by chemiluminescence in the
presence of lucigenin and luminol
to detect superoxide anion and
hydroxyl radical production,
respectively). Data are presented
as means±SEM. Asterisk
indicates P<0.05 vs. saline,
Student t- test
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Gingival healing after tooth extraction
Six weeks after the tooth extraction, intact mucosa could be
observed in 8/10 of the control animals (the average healing
score was 0.25±0.25), but different degrees of mucosal
healing disorders were detected in all (10/10) of the ZOL-
treated animals. The severity of the healing disorders reached
a score of 1.83±0.18 in this group (p<0.01).
Incidence and severity of mandibular osteonecrosis
Normal bony regeneration with a radiolucent areas of 12.09±
1.91 % of the alveolar bone could be detected at the site of the
earlier tooth extraction in all (10/10) of the saline-treated
animals. In contrast, a certain degree of discontinuity of the
cortical and spongious bone regions was found in 7/10 of the
ZOL-treated animals (Fig. 4). This higher incidence of im-
paired bony regeneration was accompanied by a significantly
lower average bone density in this group (39.51±7.18 % of
the alveolar area) as compared with that in the saline-treated
group (p<0.01).
The radiological diagnosis of mandibular osteonecrosis
was confirmed by standard histological examinations
(Fig. 5). Findings of missing nuclear staining in the osteocytes
increased inflammatory infiltration and granulation tissue for-
mation around the necrotic area, and occasional sequester
formation were made in 6/10 of the ZOL-treated animals,
whereas nearly normal bone regeneration was observed in
the other rats.
Discussion
The major aim of the present study was to examine the
mandibular periosteal microcirculatory reactions in a ro-
dent model of MRONJ. Through the chronic administra-
tion of high i.v. doses of ZOL in combination with an
invasive dental intervention, a high prevalence of mucosal
healing disorders (∼100 %) was achieved together with a
relatively high osteonecrosis rate (70 %; as revealed by
micro-CT and histological analyses). This protocol was
based on a modified literature method [14]. BIS doses in
the range 20–2250 μg/kg with different frequencies and
different administration routes have been administered by
others (for a meta-analysis [15]). The relatively high dose
applied here (80 μg/kg/week) is still well tolerated in rats,
and although it was also administered in a higher frequen-
cy than on human use, it produced symptoms and radio-
logical evidence similar to those observed in humans.
Apart from the dose of ZOL, the relatively high incidence
of MRONJ in this study can be explained by (1) the
triggering effect of the applied dental extraction (the
Table 2 The effects of chronic ZOL treatment on the leukocyte count,
neutrophil-derived CD11b adhesion molecule expression and plasma
TNF-alpha levels
Parameter Saline ZOL P values
PMN leukocyte count in
the blood (cells/μl)
4513±250 3731±215 <0.05
CD11b expression (mean
fluorescence intensity)
1.57±0.21 1.37±0.09 n. s.
TNF-alpha (pg/ml) 2.65±0.49 2.33±0.39 n. s.
Data are presented as mean±SEM. P<0.05 vs. saline, Student t test
n. s. not significant
Fig. 4 Bone density differences expressed as a percentage of the radio-
lucent area of the alveolar bone (marked with a rectangle) in saline- and
BIS-treated animals 6 weeks after tooth extraction (a). Data are presented
as means±SEM. Asterisk indicates P<0.05 vs. saline, Student t test.
Micro-CT scans show representative images of the mandibular cross-
sections in saline- and ZOL-treated rats (b and c, respectively)
Clin Oral Invest
importance of which has been demonstrated in MRONJ
patients) [3]) and (2) the use of the mandibular site (there
is a higher prevalence of osteonecrosis at this localization
in humans) [16].
It is reasonable to assume that impaired regeneration pro-
cesses contribute to the pathophysiology of MRONJ. From a
functional aspect, bony regeneration processes depend not
only on the functional activity of the osteoblasts and
osteoclasts but also on the blood supply and angiogenesis.
BISs have been shown to influence all of these processes. As
such, the inhibition of osteoclast recruitment to the bone
surface [17] and shortening of the osteoclast life span are the
main effects of BISs that are brought about directly or indi-
rectly (via the OPG-RANKL pathway) [18]. Accordingly,
delayed bone healing [19, 20], together with decreased bone
formation and vascularity in the extraction socket, have been
detected in ZOL-treated rats [21]. Numerous studies have
elucidated the antiangiogenic effects of BIS both in vitro
[22] and in vivo [20, 23]. Furthermore, thicker and less
connected/ordered blood vessels in the alveolar bone of the
mandible were found in ZOL-treated rats after tooth extraction
[24]. The aim of the present study was to assess not the
structural but the functional aspects of chronic BIS treatment
on the microvasculature.
Direct toxic and inflammatory effects of BISs may also
contribute to the development of MRONJ. BISs exert toxic
effects on many different cell types (fibroblasts, osteoblasts,
and endothelial and epithelial cells), manifested in diminished
cell proliferation and decreased collagen production, ZOL
being the most inhibitory in this respect [25–27]. Furthermore,
marked inflammatory reactions are attributed to BISs through
the induction of peritonitis via the activation of immunologi-
cal pathways after intraperitoneal administration [5, 6, 28].
Enhanced leukocyte–endothelial interactions have been dem-
onstrated by means of IVM after BIS treatment in an arthritis
model in mice [7]. BIS-associated inflammatory bony chang-
es have also been detected in the mandible [9, 29]. Interest-
ingly, these inflammatory changes were limited to the mandi-
ble and were not seen in the femur or the tibia [9, 29]. High-
dose ZOL exacerbates the inflammatory response in a peri-
odontitis model, where the bone lesions strikingly resemble
MRONJ [21]. In the present study, pro-inflammatory aspects
of chronic BIS treatment could also be traced in the mandib-
ular periosteum, and histological analysis supported the infil-
tration of the tissue by leukocytes in the neighboring necrotic
zone.
In this microsurgical model, the periosteal microcirculation
of the mandible can be visualized relatively easily in the molar
region, which is likewise a cardinal localization of MRONJ
[3]. Apart from nutritive considerations, the periosteum is
important for its osteoprogenitor cell content during bone
regeneration. Although BISs exert effects on osteoblast pro-
liferation, differentiation and migration in the entire skeleton
[30], their action seems to depend on the anatomical location,
with the jawbones as highly frequent sites of osteonecrosis.
After prolonged use, BISs are known to accumulate in the
skeleton, reaching the highest concentration in the mandible
[25, 31], which may explain their potential toxic effects pre-
dominantly in the jawbones. Furthermore, osteoblasts have
different proliferation properties at different locations (appen-
dicular vs. axial bones) under physiological circumstances,
Fig. 5 Representative micrograph (H&E staining) showing regeneration
processes in a ZOL-treated animal 6 weeks after tooth extraction (mag-
nification ×4) (a). s salivary gland, m muscle, b bone, g gingiva, ct
connective tissue. Sequester formation (se) and lack of nuclear staining
of the necrotic bone (nb) and PMN granulocyte infiltration around the
necrotic area (center of the section) can be seen at higher magnifications
(magnifications ×10 and 40) (b, and c, respectively). The bar denotes
200 μm
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and this phenomenon is also critically influenced by BIS
treatment [32]. The functional activity of the osteocytes too
differs between the mandible and the tibia [33], and the
aggravating effects of BISs on bone healing are confined to
the jaw [34]. Although the above findings reveal certain
potential factors contributing to the higher incidence of
osteonecrosis of the jawbones, the exact pathomechanism is
unknown.
As opposed to the microcirculatory consequences of bone
injury (i.e. fractures) [35], the effects of tooth extraction on the
microcirculatory derangement and local inflammation are less
commonly described, due to methodological constraints. We
focus here on the microcirculatory aspects of chronic ZOL
treatment combined with an earlier local trauma of the jaw
(tooth extraction). IVM data were obtained in the proximity of
the injury and from a contralateral (intact) site on the mandib-
ular periosteum and were compared with those relating to the
intact tibia. After chronic ZOL treatment, increased degrees of
leukocyte–endothelial interactions (rolling and adhesion)
were observed in the mandibular periosteum, both at the site
of the earlier tooth extraction and at the contralateral site, but
the corresponding interactions in the tibia were less extensive.
It is still an unanswered question why the examined cell-to-
cell interactions are higher in the postcapillary venules of the
mandible, irrespectively of the proximity of the tooth extrac-
tion site and the presence of MRONJ in the ZOL-treated
group. In preliminary studies, we did not observe inflamma-
tory complications in the mandibular periosteum without
tooth extraction, which demonstrated the triggering effect of
the trauma in this region. This observation was supported by
further findings, when more intense inflammatory reactions of
ZOL were evolved in the acute phase after tooth extraction
(data not shown). The inflammatory processes were similarly
shown in an IVM study to be aggravated by a BIS in an
arthritis model in mice [7]. Elevated levels of the pro-
inflammatory cytokine TNF-alpha have been reported in hu-
man patients in response to certain types of BISs [8] but were
not detected after the chronic administration of a BIS in our
study. Furthermore, the number and functional activity (free
radical-producing capacity) of PMNs were moderately re-
duced here. Such effects on the free radical-producing poten-
tial of PMNs (including NADPH-oxidase activity) have also
been demonstrated by others [36, 37]. Favot et al. suggested
that the compromised neutrophil functions, too, may be used
as potential biomarkers for MRONJ susceptibility [38]. Inter-
estingly, others have found impaired neutrophil chemotaxis
after BIS exposure in mice [36] and humans [38], and this
parameter is influenced most extensively by ZOL among the
different types of BISs [39]. For leukocyte–endothelial inter-
actions (as seen in our study), an enhanced expression of
adhesion molecules is required on the surface of the endothe-
lial cells and/or neutrophil leukocytes [40]. Interestingly, ex-
pression of the neutrophil-derived adhesion molecule CD11b
(responsible for leukocyte adherence) was not found to be
influenced by chronic ZOL treatment here or in other studies.
The extents of these inflammatory reactions, however, dif-
fered in the jaw and the tibial regions. These regional differ-
ences might be explained by different degrees of endothelium-
derived adhesion molecule expression at the different anatom-
ical locations.
Conclusions
A causative relationship between the microcirculatory inflam-
matory reactions and the pathogenesis of MRONJ could not
be provided in the present study; regional differences in en-
dothelial function/dysfunction, however, may contribute to
the explanation of differences in the occurrence of
osteonecrosis seen at different anatomical locations.
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Use of antibiotic beads in the management of bisphosphonate-
related osteonecrosis of the jaw
M. Esquillo 1,2,3
1 Philippine College Of Oral And Maxillofacial Surgeons,
Philippines
2 DLS-STI Medical Center, Philippines
3 Manila Central University, Philippines
Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ)
is a severe complication described as an area of bone in the jaw
that has necrosed and been exposed in the mouth for more than
eight weeks in a person taking bisphosphonate. Surgical debride-
ment or resection in combinationwith antibiotic therapy is advised
to resolve the acute infection and pain as well as for long-term
palliation, particularly for stage 3 cases. The use of antibiotic
beads in the management of osteomyelitis, which has similar clin-
ical features with BRONJ, has been described previously. It is
hypothesized that the use of antibiotic beads may be beneﬁcial
in the management of BRONJ. Two cases diagnosed with stage 3
BRONJ were managed with the use of antibiotic beads. Treatment
protocol consists of thoroughdebridement and curettage to remove
infected and necrotic tissue, placement of antibiotic beads, and
primary closure of the wound. Removal of the antibiotic beads is
then performed after six weeks. Both cases resolved uneventfully.
Results suggest that the use of antibiotic beads canbe a viable treat-
ment option in the surgical management of stage 3 BRONJ cases.
Further clinical and experimental studies are needed to elucidate
the exact relationship and mechanisms involved.
Key words antibiotic beads; bisphosphonate; Bronj;
osteonecrosis
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Microcirculatory consequences of chronic bisphosphonate
treatment after tooth extraction in a rat model
A. Janovszky1,∗, R. Varga1, A. Szabó2, D. Garab2, M. Boros 2,
J. Piffkó1
1 Department ofOral andMaxillofacial Surgery,Hungary, Europe
2 Institute of Surgical Research, University of Szeged, Szeged,
Hungary, Europe
Background and objectives: Bisphosphonates (BIS) has a
beneﬁcial effect in patients whosuffer from osteoporosis and bone
metastasis, however, adverse consequences such as osteonecrosis
of the jawmayoccur. Our aim was to assess whether inﬂammatory
processes mediated by microcirculatory dysfunction are associ-
atedwith the development ofBIS-relatedosteonecrosis. This study
evaluated themicrocirculatory effects of BIS in the mandibular
periosteum after standardizeddental procedures, and in the tib-
ialperiosteum in order to compare the effects of BIS in different
osseous locations.
Methods: Sprague-Dawley rats were randomly allotted into
vehicle-treated control (n= 15) or chronic BIS-treated (ivzole-
dronate, 80 g/kg once a week, over eight weeks, n= 20)
groups, respectively. At the end of the chronic treatment, ﬁrst
molarextraction was performed at one side of the mandible.
Leukocyte–endothelial interactions were measured at both sides
of mandibular periosteum by intravital ﬂuorescence video
microscopy as well as in the tibial periosteum. Systemic, inﬂam-
matory parameters were measured such as NADPH-oxidase
activity of neutrophil leukocytes by luminometry, expression of
neutrophil-derived adhesion molecule CD11b by ﬂow cytometry,
and plasma levels of TNF-? by ELISA.
Results: Spontaneous osteonecrosis of the jaw could not be
revealed bymicroCT due to BIS. BIS administration increased the
leukocyte–endothelial interactionsin the mandibular postcapillary
venules compared to the control and tibial periosteum. Accord-
ing to the acute dental procedure, these inﬂammatory reactions
showed a remarkable elevation. NADPH oxidase activity was sig-
niﬁcantly lower compared to the control. Other parameters were
not affected by BIS treatment.
Conclusion: These data provide evidence that chronic BIS
treatment is accompanied by characteristic mandibular periosteal
microcirculatory inﬂammatory reactionswhich are enhanced after
an acute dental procedure. This suggests a potential role for leuko-
cytes in the pathogenesis of BIS-induced osteonecrosis.
Grant support: TÁMOP4.2.4.A/2-11-1-2012-0001, TÁMOP
4.2.2A-11/1/KONV-2012-0035, TÁMOP 4.2.2A-11/1/KONV-
2012-0073
Key words: bisphosphonate-related osteonecrosis of the jaw,
rat, microcirculatory inﬂammation, tooth extraction
http://dx.doi.org/10.1016/j.ijom.2013.07.068
T3.OR009
Epidemiological, clinical, histological, radiological and treat-
ment overview of bronj cases from territory of central serbia
and montenegro
D. Jelovac1,∗, S. Antic 1, M. Petrovic 1, M. Antunovic 2, M.
Gavric 1
1 Faculty of Dental Medicine
2 Faculty of Medicine, Montenegro
Bisphosphonates are drugs used in treatment of different
pathological conditions that affect bones, such as osteoporo-
sis, metastatic bone disease, Paget disease and osteogenesis
imperfecta, etc. The aim of the study is to present epidemiolog-
ical, radiological, clinical, histopathological data and treatment
overview of patients with BRONJ in Serbia and Montenegro.
From year 2009 to 2012 at the Clinic for Maxillofacial surgery
– Faculty of Dentistry, University of Belgrade and Podgorica 9
patients were referred to Clinics due to BRONJ, as non-healing
wound in the jaw after tooth extraction. Among them, 8 were
oncological (two patients with breast carcinoma (22.2%), three
patients with prostate carcinoma (33.3%), two multiple myeloma
patients (22.2%) and one patient with MTC (11.1%)) and one
suffering from osteoporosis (11.1%), which underwent BPs ther-
apy. Sex, age, underlying diagnosis, type of BPs therapy, dosage,
duration andway of administration, additional therapy, location of
osteonecrosis, clinical symptoms and dental extraction were ana-
lyzed parameters (age range (from 37 to 84 years); male to female
ratio was (6:3). Obtained data showed that 8 of 9 our patients
received Zometa (88.9%) (Zoledronic acid), except one woman
(11.1%) who received Bonviva (Ibandronic acid). Female patient
who receivedBonvivawas the only patient that had nomalignancy,
and received bisphosphonates orally because of osteoporosis. The
time passed between periods of extraction to the periodwhen signs
of bone necrosis were observed ranged from 0 to 5months. Radio-
graphic ﬁndings displayed either radiolucent osteolytic zones, or
superﬁcial bone defects, that were consonant with bone necro-
sis.Histological examination excludedmalignancy.Weperformed
